Anti-TF antibody and Anti-TF antibody-drug conjugate and medical use thereof
Patent Information
- Application Number
- MYPI2025006534
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-11-14
- Filing Date
- 2024-04-26
- Publication Date
- 2024-10-28
AI Technical Summary
Existing technologies are difficult to effectively inhibit the high expression of TF and thrombosis in tumors, leading to tumor growth and poor prognosis.
Develop anti-TF antibodies and anti-TF antibody-drug conjugates to specifically bind TF, block its signaling pathway, and inhibit tumor growth and thrombosis.
It achieves specific targeted killing of TF, inhibits tumor growth and thrombosis, and has good efficacy and low toxic and side effects.
Smart Images

Figure PI2025006534_DRAWING_001 
Figure PI2025006534_DRAWING_002
Abstract
Description
Anti-TF antibodies and anti-TF antibody-drug conjugates and their medical uses Technical Field
[0001] The present disclosure relates to anti-TF antibodies and anti-TF antibody-drug conjugates and their medical uses. Background Art
[0002] The statements herein merely provide background information related to the present disclosure and do not necessarily constitute prior art.
[0003] Tissue Factor, also known as TF / tissue thromboplastin / FIII / CD142, is a 47kDa transmembrane glycoprotein consisting of 219 amino acids in the extracellular domain, 23 amino acids in the transmembrane domain, and 21 amino acids in the intracellular domain. The gene for human Tissue Factor is F3.
[0004] TF is primarily expressed by perivascular cells (such as adventitial fibroblasts and pericytes) and body surfaces (such as skin keratinocytes), but is also expressed by monocytes, brain astrocytes, lung epithelial cells, cardiac fibroblasts, and cardiomyocytes. This widespread expression facilitates its formation of a systemic hemostatic barrier.
[0005] Under normal physiological conditions, TF is the initiator of extrinsic coagulation and serves as a cellular receptor for FVII (coagulation factor VII) and its activated form, FVIIa, in the blood. When a blood vessel is damaged, TF forms a complex with FVII in the blood and activates FVII to FVIIa, forming the TF / FVIIa complex. TF / FVIIa binds to FX (coagulation factor X) in the blood, activating it to FXa and forming the TF / FVIIa / FXa complex, which further triggers the coagulation cascade and activates prothrombin (FII) to thrombin (FIIa). Thrombin converts fibrinogen into insoluble fibrin, ultimately completing coagulation.
[0006] The TF / FVIIa complex activates the PAR2 (proteinase-activated receptors 2) signaling pathway and also forms a TF / FVIIa / Integrinβ1 complex with Integrinβ1. The downstream signaling pathways of PAR2 and Integrinβ1 can promote tumor growth. Thrombin and fibrin, downstream products of the TF / FVIIa coagulation cascade, are associated with tumor metastasis and thrombosis.
[0007] Under pathological conditions, TF is highly expressed in a variety of solid tumors, including pancreatic, lung, breast, gastric, colorectal, liver, esophageal, ovarian, and bladder cancers. Various growth factors and cytokines induce TF expression, while a variety of transcription factors and microRNAs regulate TF gene expression in cancer cells. For example, the hepatocyte growth factor (HGF) / c-Met and epidermal growth factor receptor (EGFR) signaling pathways can upregulate TF expression by activating multiple kinase pathways, including JNK, Src, PI3k / Akt / mTOR, and KRAS / Raf / MEK / ERK. Transforming growth factor β (TGF-β) and vascular endothelial growth factor (VEGF) can also increase TF expression. During inflammation, TF can be upregulated by various cytokines, such as interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). TF can also be downregulated by some microRNAs such as miR-181b, miR19, etc., or its activity can be inhibited by TFPI (tissue factor pathway inhibitor) on monocytes.
[0008] High expression of TF under pathological conditions can promote tumor growth, metastasis, and thrombosis, and is associated with poor prognosis. Therefore, the development of ADCs targeting TF can not only inhibit tumor growth through the signal blocking effect of antibodies, but also achieve tumor-specific killing of toxins through the targeting of TF antibodies.
[0009] Summary of the Invention
[0010] The present disclosure relates to anti-TF antibodies, anti-TF antibody-drug conjugates (especially anti-TF antibody-exitecan analog conjugates) and their medical uses.
[0011] The present disclosure provides an anti-TF antibody, wherein the anti-TF antibody comprises a heavy chain variable region and a light chain variable region, wherein:
[0012] a. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 40, HCDR2 comprises the amino acid sequence of SEQ ID NO: 64 or 41, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 65 or 42, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 66 or 43, LCDR2 comprises the amino acid sequence of SEQ ID NO: 67 or 44, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 68, 83 or 45;
[0013] b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 46, HCDR2 comprises the amino acid sequence of SEQ ID NO: 47, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 48, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 49, 111, 112 or 113, LCDR2 comprises the amino acid sequence of SEQ ID NO: 50, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 51;
[0014] c. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 73 or 144, HCDR2 comprises the amino acid sequence of SEQ ID NO: 74, 142, 145 or 146, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 75 or 143, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 76, 151, 147 or 150, LCDR2 comprises the amino acid sequence of SEQ ID NO: 77 or 148, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 78 or 149;
[0015] Preferably,
[0016] a. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 40, HCDR2 comprises the amino acid sequence of SEQ ID NO: 64, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 65, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 66, LCDR2 comprises the amino acid sequence of SEQ ID NO: 67, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 68 or 83; or
[0017] the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 40, HCDR2 comprises the amino acid sequence of SEQ ID NO: 41, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 42, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 43, LCDR2 comprises the amino acid sequence of SEQ ID NO: 44, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 45;
[0018] b. the heavy chain variable region HCDR1 comprises the amino acid sequence of SEQ ID NO: 46, HCDR2 comprises the amino acid sequence of SEQ ID NO: 47, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 48, and the light chain variable region LCDR1 comprises the amino acid sequence of SEQ ID NO: 49, LCDR2 comprises the amino acid sequence of SEQ ID NO: 50, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 51;
[0019] c. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 73, HCDR2 comprises the amino acid sequence of SEQ ID NO: 74, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 75, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 76 or 151, LCDR2 comprises the amino acid sequence of SEQ ID NO: 77 or 148, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 78.
[0020] In some embodiments, the anti-TF antibody as described above, wherein the HCDRs 1-3 and LCDRs 1-3 as described above are determined according to the Kabat numbering convention. In some embodiments, the anti-TF antibody as described above, wherein the HCDRs 1-3 and LCDRs 1-3 as described above are determined according to the IMGT numbering convention. In some embodiments, the anti-TF antibody as described above, wherein the HCDRs 1-3 and LCDRs 1-3 as described above are determined according to the Chothia numbering convention. In some embodiments, the anti-TF antibody as described above, wherein the HCDRs 1-3 and LCDRs 1-3 as described above are determined according to the AbM numbering convention. In some embodiments, the anti-TF antibody as described above, wherein the HCDRs 1-3 and LCDRs 1-3 as described above are determined according to the Contact numbering convention.
[0021] The present disclosure provides an anti-TF antibody, wherein the anti-TF antibody comprises a heavy chain variable region and a light chain variable region, wherein:
[0022] a. the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 40, SEQ ID NO: 64 and SEQ ID NO: 65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 66, SEQ ID NO: 67 and SEQ ID NO: 68, respectively; or
[0023] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:40, SEQ ID NO:64 and SEQ ID NO:65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:83, respectively; or
[0024] The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42, respectively; the light chain variable region comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45, respectively;
[0025] b. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 48, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51, respectively;
[0026] c. the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 73, SEQ ID NO: 74 and SEQ ID NO: 75, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 76, SEQ ID NO: 77 and SEQ ID NO: 78, respectively; or
[0027] The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO: 73, SEQ ID NO: 74, and SEQ ID NO: 75, respectively; the light chain variable region comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO: 151, SEQ ID NO: 148, and SEQ ID NO: 78, respectively;
[0028] HCDR1-3 and LCDR1-3 as described above are identified according to the Kabat numbering convention.
[0029] The present disclosure provides an anti-TF antibody, wherein the anti-TF antibody comprises a heavy chain variable region and a light chain variable region, wherein:
[0030] a. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 40, SEQ ID NO: 64 and SEQ ID NO: 65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 66, SEQ ID NO: 67 and SEQ ID NO: 68, respectively;
[0031] b. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 48, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51, respectively;
[0032] c. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:73, SEQ ID NO:74 and SEQ ID NO:75, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:76, SEQ ID NO:77 and SEQ ID NO:78, respectively.
[0033] In some embodiments, the anti-TF antibody as described above is a murine antibody, a chimeric antibody, or a humanized antibody.
[0034] In some embodiments, the anti-TF antibody as described above is a chimeric antibody or a humanized antibody.
[0035] In some embodiments, the anti-TF antibody as described above is a humanized antibody.
[0036] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0037] a. the heavy chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 62, 58, 130, 131, or 132, and the light chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 63, 81, 59, 133, 134, or 135; or the heavy chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 36, and the light chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 37;
[0038] b. the heavy chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 52 or 114, and the light chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 53, 115, 116, 117, 118, 119, 120, or 121; or the heavy chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 38, and the light chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO: 39;
[0039] c. the heavy chain variable region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 71, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, or 96, and the light chain variable region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 72, 97, 102, 98, 99, 100, or 101;
[0040] Preferably,
[0041] a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 62, 58, 130, 131 or 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 63, 81, 59, 133, 134 or 135; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 37;
[0042] b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 52 or 114, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 53, 115, 116, 117, 118, 119, 120, or 121; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 38, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39;
[0043] c. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 71, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 or 96, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72, 97, 102, 98, 99, 100 or 101;
[0044] More preferably,
[0045] a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 62, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 63 or 81; or
[0046] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or
[0047] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 37; or
[0048] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or
[0049] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or
[0050] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or
[0051] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or
[0052] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or
[0053] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or
[0054] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or
[0055] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or
[0056] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or
[0057] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or
[0058] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or
[0059] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; or
[0060] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; or
[0061] The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; or
[0062] the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135;
[0063] b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 52, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 53; or
[0064] the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 38, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39;
[0065] c. The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72, 97 or 102.
[0066] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0067] a. the heavy chain variable region is shown in SEQ ID NO: 36; and the light chain variable region is shown in SEQ ID NO: 37; or
[0068] b. The heavy chain variable region is shown in SEQ ID NO: 38; and the light chain variable region is shown in SEQ ID NO: 39.
[0069] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0070] a. the heavy chain variable region is shown in SEQ ID NO: 62; and the light chain variable region is shown in SEQ ID NO: 63; or
[0071] The heavy chain variable region is shown in SEQ ID NO: 62; and the light chain variable region is shown in SEQ ID NO: 81; or
[0072] The heavy chain variable region is shown in SEQ ID NO: 58; and the light chain variable region is shown in SEQ ID NO: 59; or
[0073] The heavy chain variable region is shown in SEQ ID NO: 36, and the light chain variable region is shown in SEQ ID NO: 37; or
[0074] The heavy chain variable region is shown in SEQ ID NO: 130, and the light chain variable region is shown in SEQ ID NO: 133; or
[0075] The heavy chain variable region is shown in SEQ ID NO: 131, and the light chain variable region is shown in SEQ ID NO: 133; or
[0076] The heavy chain variable region is shown in SEQ ID NO: 58, and the light chain variable region is shown in SEQ ID NO: 133; or
[0077] The heavy chain variable region is shown in SEQ ID NO: 132, and the light chain variable region is shown in SEQ ID NO: 133; or
[0078] The heavy chain variable region is shown in SEQ ID NO: 130, and the light chain variable region is shown in SEQ ID NO: 134; or
[0079] The heavy chain variable region is shown in SEQ ID NO: 131, and the light chain variable region is shown in SEQ ID NO: 134; or
[0080] The heavy chain variable region is shown in SEQ ID NO: 58, and the light chain variable region is shown in SEQ ID NO: 134; or
[0081] The heavy chain variable region is shown in SEQ ID NO: 132, and the light chain variable region is shown in SEQ ID NO: 134; or
[0082] The heavy chain variable region is shown in SEQ ID NO: 130, and the light chain variable region is shown in SEQ ID NO: 59; or
[0083] The heavy chain variable region is shown in SEQ ID NO: 131, and the light chain variable region is shown in SEQ ID NO: 59; or
[0084] The heavy chain variable region is shown in SEQ ID NO: 132, and the light chain variable region is shown in SEQ ID NO: 59; or
[0085] The heavy chain variable region is shown in SEQ ID NO: 130, and the light chain variable region is shown in SEQ ID NO: 135; or
[0086] The heavy chain variable region is shown in SEQ ID NO: 131, and the light chain variable region is shown in SEQ ID NO: 135; or
[0087] The heavy chain variable region is shown in SEQ ID NO: 58, and the light chain variable region is shown in SEQ ID NO: 135; or
[0088] The heavy chain variable region is shown in SEQ ID NO: 132, and the light chain variable region is shown in SEQ ID NO: 135;
[0089] b. the heavy chain variable region is shown in SEQ ID NO: 52; and the light chain variable region is shown in SEQ ID NO: 53; or
[0090] The heavy chain variable region is shown in SEQ ID NO: 38, and the light chain variable region is shown in SEQ ID NO: 39;
[0091] c. the heavy chain variable region is shown in SEQ ID NO: 71; and the light chain variable region is shown in SEQ ID NO: 72; or
[0092] The heavy chain variable region is shown in SEQ ID NO: 71; and the light chain variable region is shown in SEQ ID NO: 97; or
[0093] The heavy chain variable region is shown in SEQ ID NO: 71; and the light chain variable region is shown in SEQ ID NO: 102.
[0094] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0095] a. the heavy chain variable region is shown in SEQ ID NO: 62; and the light chain variable region is shown in SEQ ID NO: 63; or
[0096] b. the heavy chain variable region is shown in SEQ ID NO: 52; and the light chain variable region is shown in SEQ ID NO: 53; or
[0097] c. The heavy chain variable region is shown in SEQ ID NO: 71; and the light chain variable region is shown in SEQ ID NO: 72.
[0098] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0099] The heavy chain variable region is selected from SEQ ID NO: 130, 131 and 132; and the light chain variable region is selected from SEQ ID NO: 133, 134 and 135.
[0100] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0101] The heavy chain variable region is selected from SEQ ID NO: 114; and the light chain variable region is selected from SEQ ID NO: 115, 116, 117, 118, 119, 120 and 121.
[0102] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain variable region and a light chain variable region, wherein:
[0103] The heavy chain variable region is selected from SEQ ID NO: 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 71, 94, 95 and 96; and the light chain variable region is selected from SEQ ID NO: 97, 98, 99, 100, 101 and 102.
[0104] In some embodiments, the anti-TF antibody as described in any of the preceding items is an antibody fragment; preferably, it is selected from Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv and dAb.
[0105] In some embodiments, the anti-TF antibody as described in any of the above items further comprises an antibody heavy chain constant region and a light chain constant region; preferably, the heavy chain constant region is selected from human IgG1, IgG2, IgG3 and IgG4 constant regions, and the light chain constant region is a human κ or λ chain constant region; more preferably, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 54, and the light chain constant region comprises the amino acid sequence of SEQ ID NO: 55.
[0106] In some embodiments, the amino acid sequence of the heavy chain constant region is shown in SEQ ID NO:54, and the amino acid sequence of the light chain constant region is shown in SEQ ID NO:55.
[0107] In some embodiments, the anti-TF antibody of any of the preceding items is selected from the antibody comprising a heavy chain and a light chain as described in any of the following:
[0108] a. a heavy chain having at least 80% sequence identity to SEQ ID NO: 69, 60, 136, 137 or 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 70, 82, 61, 139, 140 or 141; or
[0109] a heavy chain having at least 80% sequence identity to SEQ ID NO: 107, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 108;
[0110] b. a heavy chain having at least 80% sequence identity to SEQ ID NO: 56 or 122, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 57, 123, 124, 125, 126, 127, 128 or 129; or
[0111] a heavy chain having at least 80% sequence identity to SEQ ID NO: 109, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 110;
[0112] c. a heavy chain having at least 80% sequence identity to SEQ ID NO: 79, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163 or 164, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 80, 165, 170, 166, 167, 168 or 169;
[0113] Preferably,
[0114] a. a heavy chain having at least 80% sequence identity with SEQ ID NO: 69, and / or a light chain having at least 80% sequence identity with SEQ ID NO: 70 or 82; or
[0115] a heavy chain having at least 80% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or
[0116] a heavy chain having at least 80% sequence identity to SEQ ID NO: 107, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 108; or
[0117] a heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 139; or
[0118] a heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 139; or
[0119] a heavy chain having at least 80% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 139; or
[0120] a heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 139; or
[0121] a heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or
[0122] a heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or
[0123] a heavy chain having at least 80% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or
[0124] a heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or
[0125] a heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or
[0126] a heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or
[0127] a heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or
[0128] a heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141; or
[0129] a heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141; or
[0130] a heavy chain having at least 80% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141; or
[0131] a heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141;
[0132] b. a heavy chain having at least 80% sequence identity to SEQ ID NO: 56, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 57; or
[0133] a heavy chain having at least 80% sequence identity to SEQ ID NO: 109, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 110;
[0134] c. a heavy chain having at least 80% sequence identity to SEQ ID NO: 79, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 80, 165 or 170;
[0135] More preferably,
[0136] a. the heavy chain comprises the amino acid sequence of SEQ ID NO: 69, and the light chain comprises the amino acid sequence of SEQ ID NO: 70; or
[0137] The heavy chain comprises the amino acid sequence of SEQ ID NO: 69, and the light chain comprises the amino acid sequence of SEQ ID NO: 82; or
[0138] The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or
[0139] The heavy chain comprises the amino acid sequence of SEQ ID NO: 107, and the light chain comprises the amino acid sequence of SEQ ID NO: 108; or
[0140] The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or
[0141] The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or
[0142] The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or
[0143] The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or
[0144] The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or
[0145] The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or
[0146] The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or
[0147] The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or
[0148] The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or
[0149] The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or
[0150] The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or
[0151] The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; or
[0152] The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; or
[0153] The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; or
[0154] The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 141;
[0155] b. the heavy chain comprises the amino acid sequence of SEQ ID NO: 56, and the light chain comprises the amino acid sequence of SEQ ID NO: 57; or
[0156] the heavy chain comprises the amino acid sequence of SEQ ID NO: 109, and the light chain comprises the amino acid sequence of SEQ ID NO: 110;
[0157] c. the heavy chain comprises the amino acid sequence of SEQ ID NO: 79, and the light chain comprises the amino acid sequence of SEQ ID NO: 80 or
[0158] The heavy chain comprises the amino acid sequence of SEQ ID NO: 79, and the light chain comprises the amino acid sequence of SEQ ID NO: 165; or
[0159] The heavy chain comprises the amino acid sequence of SEQ ID NO: 79, and the light chain comprises the amino acid sequence of SEQ ID NO: 170.
[0160] The above-mentioned "at least 80% sequence identity" includes at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
[0161] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain and a light chain, wherein:
[0162] a. a heavy chain having at least 85% sequence identity with SEQ ID NO: 69, and / or a light chain having at least 85% sequence identity with SEQ ID NO: 70; or
[0163] a heavy chain having at least 85% sequence identity to SEQ ID NO: 69, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 82; or
[0164] a heavy chain having at least 85% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 61; or
[0165] a heavy chain having at least 85% sequence identity to SEQ ID NO: 107, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 108; or
[0166] a heavy chain having at least 85% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 139; or
[0167] a heavy chain having at least 85% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 139; or
[0168] a heavy chain having at least 85% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 139; or
[0169] a heavy chain having at least 85% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 139; or
[0170] a heavy chain having at least 85% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 140; or
[0171] a heavy chain having at least 85% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 140; or
[0172] a heavy chain having at least 85% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 140; or
[0173] a heavy chain having at least 85% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 140; or
[0174] a heavy chain having at least 85% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 61; or
[0175] a heavy chain having at least 85% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 61; or
[0176] a heavy chain having at least 85% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 61; or
[0177] a heavy chain having at least 85% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 141; or
[0178] a heavy chain having at least 85% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 141; or
[0179] a heavy chain having at least 85% sequence identity to SEQ ID NO: 60, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 141; or
[0180] a heavy chain having at least 85% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 141;
[0181] b. a heavy chain having at least 85% sequence identity to SEQ ID NO: 56, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 57; or
[0182] a heavy chain having at least 85% sequence identity to SEQ ID NO: 109, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 110;
[0183] c. a heavy chain having at least 85% sequence identity to SEQ ID NO: 79, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 80; or
[0184] a heavy chain having at least 85% sequence identity to SEQ ID NO: 79, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 165; or
[0185] A heavy chain having at least 85% sequence identity to SEQ ID NO: 79, and / or a light chain having at least 85% sequence identity to SEQ ID NO: 170.
[0186] The above-mentioned "at least 85% sequence identity" includes at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity.
[0187] In some embodiments, the anti-TF antibody of any of the preceding items is selected from the antibody comprising a heavy chain and a light chain as described in any of the following:
[0188] a. The heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 70; or
[0189] The heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 82; or
[0190] The heavy chain is shown in SEQ ID NO: 60; and the light chain is shown in SEQ ID NO: 61; or
[0191] The heavy chain is shown in SEQ ID NO: 107, and the light chain is shown in SEQ ID NO: 108; or
[0192] The heavy chain is shown in SEQ ID NO: 136, and the light chain is shown in SEQ ID NO: 139; or
[0193] The heavy chain is shown in SEQ ID NO: 137, and the light chain is shown in SEQ ID NO: 139; or
[0194] The heavy chain is shown in SEQ ID NO: 60, and the light chain is shown in SEQ ID NO: 139; or
[0195] The heavy chain is shown in SEQ ID NO: 138, and the light chain is shown in SEQ ID NO: 139; or
[0196] The heavy chain is shown in SEQ ID NO: 136, and the light chain is shown in SEQ ID NO: 140; or
[0197] The heavy chain is shown in SEQ ID NO: 137, and the light chain is shown in SEQ ID NO: 140; or
[0198] The heavy chain is shown in SEQ ID NO: 60, and the light chain is shown in SEQ ID NO: 140; or
[0199] The heavy chain is shown in SEQ ID NO: 138, and the light chain is shown in SEQ ID NO: 140; or
[0200] The heavy chain is shown in SEQ ID NO: 136, and the light chain is shown in SEQ ID NO: 61; or
[0201] The heavy chain is shown in SEQ ID NO: 137, and the light chain is shown in SEQ ID NO: 61; or
[0202] The heavy chain is shown in SEQ ID NO: 138 and / or SEQ ID NO: 61; or
[0203] The heavy chain is shown in SEQ ID NO: 136, and the light chain is shown in SEQ ID NO: 141; or
[0204] The heavy chain is shown in SEQ ID NO: 137, and the light chain is shown in SEQ ID NO: 141; or
[0205] The heavy chain is shown in SEQ ID NO: 60, and the light chain is shown in SEQ ID NO: 141; or
[0206] The heavy chain is shown in SEQ ID NO: 138, and the light chain is shown in SEQ ID NO: 141;
[0207] b. The heavy chain is shown in SEQ ID NO: 56; and the light chain is shown in SEQ ID NO: 57; or
[0208] The heavy chain is shown in SEQ ID NO: 109, and the light chain is shown in SEQ ID NO: 110;
[0209] c. the heavy chain is shown in SEQ ID NO: 79; and the light chain is shown in SEQ ID NO: 80; or
[0210] The heavy chain is shown in SEQ ID NO: 79; and the light chain is shown in SEQ ID NO: 165; or
[0211] The heavy chain is shown in SEQ ID NO: 79; and the light chain is shown in SEQ ID NO: 170.
[0212] In some embodiments, the anti-TF antibody of any of the preceding items comprises a heavy chain and a light chain:
[0213] a. The heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 70;
[0214] b. The heavy chain is shown in SEQ ID NO: 56; and the light chain is shown in SEQ ID NO: 57;
[0215] c. The heavy chain is shown in SEQ ID NO: 79; and the light chain is shown in SEQ ID NO: 80.
[0216] In some embodiments, the present disclosure also provides a nucleic acid molecule encoding an anti-TF antibody as described in any of the preceding items.
[0217] In some embodiments, the present disclosure also provides a host cell comprising the nucleic acid molecule as described above.
[0218] In some embodiments, the present disclosure further provides an immunoconjugate comprising the anti-TF antibody as described in any of the preceding items and an effector molecule, wherein the effector molecule is conjugated to the anti-TF antibody as described in any of the preceding items; preferably, the effector molecule is selected from anti-tumor agents, immunomodulators, biological response modifiers, lectins, cytotoxic drugs, chromophores, fluorophores, chemiluminescent compounds, enzymes, metal ions, and any combination thereof.
[0219] In some embodiments, the present disclosure also provides a method for in vivo and / or in vitro immunodetection or determination of TF, comprising the step of contacting the anti-TF antibody according to any of the preceding items with a subject or a sample from a subject.
[0220] In some embodiments, the present disclosure further provides an antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof:
[0221] in:
[0222] Y is -O-(CR a R b ) m -CR 1 R 2-C(O)-;
[0223] Among them, R a and R b are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, halogens and C 1-6 alkyl;
[0224] R 1 C 3-6 Cycloalkyl-C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0225] R 2 Selected from hydrogen atoms, halogenated C 1-6 Alkyl and C 3-6 Cycloalkyl;
[0226] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl;
[0227] m is an integer from 0 to 4;
[0228] L is the joint unit;
[0229] n is 1 to 10; preferably, n is 1 to 8; more preferably, n is 2 to 8; most preferably, n is 4 to 8;
[0230] Pc is the anti-TF antibody as described in any of the preceding items.
[0231] In some embodiments, n is an average value of 0-10 (including decimals and integers), preferably 1-10, more preferably 1-8, or 2-8, or 2-7, 2-6, or 2-5, or 2-4, or 3-8, or 3-7, or 3-6, or 4-8, or 4-7, or 4-6, or 4-5; in some embodiments, n is an average value, such as 1, 2, 3, 4, 5, 6, 7, 8, 9, 10.
[0232] In some embodiments, R a and R b are the same or different and are each independently selected from hydrogen, halogen and C 1-6 Alkyl; preferably, R a and R b The same or different, and each independently a hydrogen atom or a C 1-6 alkyl.
[0233] In some embodiments, R 1 C 3-6 Cycloalkyl; preferably, R 1 It is cyclopropyl.
[0234] In some embodiments, R 2 is a hydrogen atom or a halogenated C 1-6 Alkyl; preferably, R 2 A hydrogen atom.
[0235] In some embodiments, R 1 and R 2 Together with the carbon atom to which it is attached, it forms a cyclopropyl group.
[0236] In some embodiments, R 1 C 3-6 Cycloalkyl, and R 2 is a hydrogen atom or a halogenated C 1-6 Alkyl; preferably, R 1 is cyclopropyl, and R 2 A hydrogen atom.
[0237] In some embodiments, the antibody-drug conjugate represented by the aforementioned general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,
[0238] Among them, L 1 Selected from -(succinimide-3-yl-N)-WC(O)-, -CH2-C(O)-NR 3 -WC(O)- and -C(O)-WC(O)-, wherein W is selected from C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 Cycloalkyl, wherein the C 1-6 Alkylene or C 1-6 Alkylene-C 3-6 The cycloalkyl groups are each independently optionally selected from halogen, hydroxy, cyano, amino, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 substituted by one or more substituents in the cycloalkyl group;
[0239] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1is an integer from 1 to 20;
[0240] L 3 is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
[0241] L 4 Selected from-NR 5 (CR 6 R 7 ) t -、-C(O)NR 5 -、-C(O)NR 5 (CH2) t - and chemical bonds, wherein t is an integer from 1 to 6;
[0242] R 3 、R 4 and R 5 are the same or different and are each independently selected from hydrogen atom, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 hydroxyalkyl;
[0243] R 6 and R 7 are the same or different and are each independently selected from hydrogen atom, halogen, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Hydroxyalkyl.
[0244] In some embodiments, L 1 -(succinimide-3-yl-N)-WC(O)-, wherein W is selected from C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 Cycloalkyl; preferably, L 1 for where s 1 is an integer from 2 to 8; more preferably, L 1 for where s 1 is 5.
[0245] In some embodiments, L 2 For chemical bonds.
[0246] In some embodiments, L 3 is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid; preferably, L 3 is a tetrapeptide residue; more preferably, L 3 is a tetrapeptide residue as shown in GGFG (SEQ ID NO: 105).
[0247] In some embodiments, L 4 Selected from-NR 5 (CR 6 R 7 ) t -, wherein t is an integer from 1 to 6; R 5 、R 6 and R 7 The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl; preferably, L 4 -NR 5 (CR 6 R 7 )t-, where R 5 、R 6 or R 7 The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl, t is 1 or 2.
[0248] In some embodiments, the antibody-drug conjugate represented by the aforementioned general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -,
[0249] Among them L 1 for where s 1 is an integer from 2 to 8;
[0250] L 2 is a chemical bond;
[0251] L 3 is a tetrapeptide residue; preferably, L 3 is a tetrapeptide residue as shown in GGFG (SEQ ID NO: 105);
[0252] L 4 -NR 5 (CR 6 R 7 )t-, where R5 、R 6 or R 7 The same or different, and each independently a hydrogen atom or a C 1-6 Alkyl, t is 1 or 2;
[0253] wherein the -L- 1 The end is connected to PC, L 4 Connect the Y end.
[0254] In some embodiments, the antibody-drug conjugate of the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items is a general formula (Pc-L a -YD) shown in the antibody - drug conjugate or a pharmaceutically acceptable salt thereof:
[0255] in,
[0256] Pc is the anti-TF antibody as described in any of the preceding items;
[0257] m is an integer from 0 to 4;
[0258] n is 1 to 10;
[0259] R 1 C 3-6 Cycloalkyl-C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0260] R 2 Selected from hydrogen atoms, halogenated C 1-6 Alkyl and C 3-6 Cycloalkyl;
[0261] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl;
[0262] W is selected from C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 Cycloalkyl, wherein the C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 The cycloalkyl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy, and cycloalkyl;
[0263] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR4 (CH2CH2O)p 1 CH2C(O)-、 -S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;
[0264] L 3 is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
[0265] R 4 and R 5 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, and a hydroxyalkyl group;
[0266] R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group.
[0267] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:
[0268] in:
[0269] n is 1 to 8;
[0270] Pc is the anti-TF antibody as described in any of the preceding items;
[0271] Preferably, the Pc is selected from any one of the following anti-TF antibodies comprising a heavy chain variable region and a light chain variable region:
[0272] a. the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 40, SEQ ID NO: 64 and SEQ ID NO: 65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 66, SEQ ID NO: 67 and SEQ ID NO: 68, respectively; or
[0273] The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:40, SEQ ID NO:64 and SEQ ID NO:65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:83, respectively; or
[0274] The heavy chain variable region comprises HCDR1, HCDR2, and HCDR3 as shown in SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42, respectively; the light chain variable region comprises LCDR1, LCDR2, and LCDR3 as shown in SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45, respectively;
[0275] b. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 48, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51, respectively;
[0276] c. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 73, SEQ ID NO: 74 and SEQ ID NO: 75, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 76, SEQ ID NO: 77 and SEQ ID NO: 78, respectively;
[0277] More preferably, the Pc is selected from any one of the following anti-TF antibodies comprising a heavy chain variable region and a light chain variable region:
[0278] a. the heavy chain variable region is shown in SEQ ID NO: 62; and the light chain variable region is shown in SEQ ID NO: 63; or
[0279] The heavy chain variable region is shown in SEQ ID NO: 62; and the light chain variable region is shown in SEQ ID NO: 81; or
[0280] The heavy chain variable region is shown in SEQ ID NO: 58; and the light chain variable region is shown in SEQ ID NO: 59; or
[0281] The heavy chain variable region is shown in SEQ ID NO: 36; and the light chain variable region is shown in SEQ ID NO: 37;
[0282] b. the heavy chain variable region is shown in SEQ ID NO: 52; and the light chain variable region is shown in SEQ ID NO: 53; or
[0283] The heavy chain variable region is shown in SEQ ID NO: 38; and the light chain variable region is shown in SEQ ID NO: 39;
[0284] c. the heavy chain variable region is shown in SEQ ID NO: 71; and the light chain variable region is shown in SEQ ID NO: 72;
[0285] Most preferably, the Pc is selected from any one of the following antibodies comprising a heavy chain and a light chain:
[0286] a. The heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 70; or
[0287] The heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 82; or
[0288] The heavy chain is shown in SEQ ID NO: 60; and the light chain is shown in SEQ ID NO: 61;
[0289] b. The heavy chain is shown in SEQ ID NO: 56; and the light chain is shown in SEQ ID NO: 57;
[0290] c. The heavy chain is shown in SEQ ID NO: 79; and the light chain is shown in SEQ ID NO: 80.
[0291] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:
[0292] in:
[0293] n is 1 to 8; preferably, n is 2 to 8; more preferably, n is 4 to 8;
[0294] Pc is the anti-TF antibody as described in any of the preceding items;
[0295] Preferably, the Pc is selected from any one of the following anti-TF antibodies comprising a heavy chain variable region and a light chain variable region:
[0296] a. the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 40, SEQ ID NO: 64 and SEQ ID NO: 65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 66, SEQ ID NO: 67 and SEQ ID NO: 68, respectively; or
[0297] b. The heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 46, SEQ ID NO: 47 and SEQ ID NO: 48, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 49, SEQ ID NO: 50 and SEQ ID NO: 51, respectively; or
[0298] c. the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO: 73, SEQ ID NO: 74 and SEQ ID NO: 75, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO: 76, SEQ ID NO: 77 and SEQ ID NO: 78, respectively; or
[0299] More preferably, the Pc is selected from any one of the following anti-TF antibodies comprising a heavy chain variable region and a light chain variable region:
[0300] a. The heavy chain variable region is shown in SEQ ID NO: 62; and the light chain variable region is shown in SEQ ID NO: 63;
[0301] b. The heavy chain variable region is shown in SEQ ID NO: 52; and the light chain variable region is shown in SEQ ID NO: 53; and
[0302] c. the heavy chain variable region is shown in SEQ ID NO: 71; and the light chain variable region is shown in SEQ ID NO: 72;
[0303] Most preferably, the Pc is selected from any one of the following antibodies comprising a heavy chain and a light chain:
[0304] a. The heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 70; or
[0305] b. The heavy chain is shown in SEQ ID NO: 56; and the light chain is shown in SEQ ID NO: 57; or
[0306] c. The heavy chain is shown in SEQ ID NO: 79; and the light chain is shown in SEQ ID NO: 80.
[0307] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:
[0308] in:
[0309] n is 1 to 8; preferably, n is 2 to 8; more preferably, n is 4 to 8;
[0310] Pc is an anti-TF antibody comprising a heavy chain variable region and a light chain variable region: the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3 as shown in SEQ ID NO:40, SEQ ID NO:64 and SEQ ID NO:65, respectively; the light chain variable region comprises LCDR1, LCDR2 and LCDR3 as shown in SEQ ID NO:66, SEQ ID NO:67 and SEQ ID NO:68, respectively.
[0311] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:
[0312] in:
[0313] n is 1 to 8; preferably, n is 2 to 8; more preferably, n is 4 to 8;
[0314] Pc is an anti-TF antibody comprising a heavy chain variable region as shown in SEQ ID NO: 62 and a light chain variable region as shown in SEQ ID NO: 63.
[0315] In some embodiments, the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items is an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof:
[0316] in:
[0317] n is 1 to 8; preferably, n is 2 to 8; more preferably, n is 4 to 8;
[0318] Pc is an anti-TF antibody comprising a heavy chain and a light chain: the heavy chain is shown in SEQ ID NO: 69; and the light chain is shown in SEQ ID NO: 70.
[0319] In some embodiments, the present disclosure also provides a method for preparing a compound of the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, comprising the following steps:
[0320] After Pc reduction, with the general formula (L a -YD) undergoes coupling reaction to obtain the compound represented by the general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof;
[0321] in:
[0322] Pc is the anti-TF antibody as described in any of the preceding items;
[0323] m is an integer from 0 to 4;
[0324] n is 1 to 10;
[0325] R 1 C 3-6 Cycloalkyl-C 1-6 Alkyl or C 3-6 Cycloalkyl;
[0326] R 2 Selected from hydrogen atoms, halogenated C 1-6 Alkyl and C 3-6 Cycloalkyl;
[0327] Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl;
[0328] W is selected from C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 Cycloalkyl, wherein the C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 The cycloalkyl groups are each independently optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy, and cycloalkyl;
[0329] L 2 Selected from-NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4(CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20;
[0330] L 3 is a peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl;
[0331] R 4 and R 5 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, and a hydroxyalkyl group;
[0332] R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group.
[0333] In some embodiments, the present disclosure further provides a method for preparing an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as represented by the general formula (Pc-9-A), comprising the following steps:
[0334] After Pc is reduced, it undergoes a coupling reaction with compound 9-A to obtain an antibody-drug conjugate represented by the general formula (Pc-9-A) or a pharmaceutically acceptable salt thereof;
[0335] in:
[0336] n is 1 to 8; preferably, n is 2 to 8; more preferably, n is 4 to 8;
[0337] Pc is the anti-TF antibody as described in any of the preceding items.
[0338] In some embodiments, the present disclosure further provides a pharmaceutical composition comprising the anti-TF antibody as described in any of the preceding items, or the nucleic acid molecule as described in any of the preceding items, or the antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable excipients, diluents, or carriers.
[0339] In some embodiments, the present disclosure further provides use of the anti-TF antibody as described in any of the preceding items, or the nucleic acid molecule as described in any of the preceding items, or the antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items; or the pharmaceutical composition as described in any of the preceding items in the preparation of a medicament for treating a TF-mediated disease or condition.
[0340] In some embodiments, the present disclosure further provides use of the anti-TF antibody as described in any of the preceding items, or the nucleic acid molecule as described in any of the preceding items, or the antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items; or the pharmaceutical composition as described in any of the preceding items in the preparation of a medicament for treating tumors or cancer.
[0341] In some embodiments, the present disclosure further provides the use of an anti-TF antibody as described in any of the preceding items, or a nucleic acid molecule as described in any of the preceding items, or an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items; or a pharmaceutical composition as described in any of the preceding items in the preparation of a medicament for treating a tumor or cancer; preferably, the tumor or cancer is selected from breast cancer, pancreatic cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), esophageal cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, bladder cancer, fallopian tube cancer, peritoneal cancer, colorectal cancer (including colon cancer and rectal cancer), head and neck cancer, and squamous cell carcinoma.
[0342] In some embodiments, the present disclosure further provides a kit comprising the anti-TF antibody as described in any of the preceding items, or the nucleic acid molecule as described in any of the preceding items, or the antibody-drug conjugate as described in any of the preceding items or a pharmaceutically acceptable salt thereof; or the pharmaceutical composition as described in any of the preceding items.
[0343] In some embodiments, in the antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof as described in any of the preceding items, m is selected from 0, 1, 2, 3 and 4 without limitation.
[0344] In some embodiments, the present disclosure also provides a method for preventing or treating a disease or condition, the method comprising administering to a subject a therapeutically effective amount of an anti-TF antibody as described in any of the preceding items, or a nucleic acid molecule as described in any of the preceding items, or an antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in any of the preceding items. In some embodiments, the disease or condition is a tumor or cancer; preferably, the disease or condition is a disease or condition associated with TF. In some embodiments, the tumor or cancer is selected from breast cancer, pancreatic cancer, lung cancer (including non-small cell lung cancer and small cell lung cancer), esophageal cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, bladder cancer, fallopian tube cancer, peritoneal cancer, colorectal cancer (including colon cancer and rectal cancer), head and neck cancer, and squamous cell carcinoma.
[0345] In another aspect, the present disclosure provides a pharmaceutical composition comprising an anti-TF antibody, antibody-drug conjugate, or pharmaceutically acceptable salt thereof as described in any of the preceding items, and one or more pharmaceutically acceptable excipients, diluents, or carriers. In some embodiments, a unit dose of the pharmaceutical composition contains 0.1 mg to 3000 mg or 1 mg to 1000 mg of the anti-TF antibody or antibody-drug conjugate as described above.
[0346] In another aspect, the present disclosure provides the antibody-drug conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising the same as any one of the preceding items as a drug.
[0347] In another aspect, the present disclosure provides an antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, for use in treating a TF-mediated disease or condition; in some embodiments, the TF-mediated disease or condition is a TF-high expressing cancer, a TF-intermediate expressing cancer, or a TF-low expressing cancer. In some embodiments, the antibody-drug conjugate as described in any of the preceding items, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, is used to treat a tumor or cancer.
[0348] On the other hand, the present disclosure further relates to a method for treating and / or preventing tumors or cancers, comprising administering to a subject in need thereof a therapeutically effective dose of an antibody-drug conjugate or a pharmaceutically acceptable salt thereof as described in any of the preceding items, or a pharmaceutical composition comprising the same; in some embodiments, the tumor or cancer is a cancer associated with high expression of TF, a cancer associated with medium expression of TF, or a cancer associated with low expression of TF.
[0349] The active compound may be formulated for administration by any appropriate route, in a unit dosage form, or in a form in which a subject can self-administer a single dose. A unit dosage form of a compound or composition of the present disclosure may be in the form of a tablet, capsule, cachet, bottled solution, powder, granules, lozenge, suppository, reconstituted powder, or liquid formulation.
[0350] The dosage of the compound or composition used in the treatment methods of the present disclosure will generally vary with the severity of the disease, the weight of the subject and the relative efficacy of the compound. However, as a general guide, a suitable unit dosage may be 0.1 mg to 1000 mg.
[0351] The pharmaceutical composition disclosed herein may contain, in addition to the active compound, one or more excipients selected from the following ingredients: fillers, diluents, binders, wetting agents, disintegrants or excipients, etc. Depending on the method of administration, the composition may contain 0.1 to 99% by weight of the active compound.
[0352] The anti-TF antibodies provided in the present disclosure have good affinity for cell surface antigens and good cellular endocytosis efficiency, and have little effect on coagulation; the anti-TF antibody-drug conjugates provided in the present disclosure have strong tumor inhibition efficiency, and have better efficacy and lower toxic side effects in animals.
[0353] Epitope analysis by FACS binding experiments showed that the antibodies disclosed herein bind to a specific epitope of TF, in particular antibody hu67Y116, which binds to a different epitope of TF than antibodies in the prior art.
[0354] Detailed Description of the Invention
[0355] the term
[0356] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Although any methods and materials similar or equivalent to those described herein can be used to practice or test the present disclosure, preferred methods and materials are described herein. When describing and claiming the present disclosure, the following terms are used in accordance with the following definitions.
[0357] When a trade name is used in this disclosure, it is intended to include the formulation of the trade name product, the drug substance and the active drug portion of the trade name product.
[0358] Unless otherwise stated, the terms used in the specification and claims have the following meanings.
[0359] The three letter and one letter codes for amino acids used in this disclosure are as described in J. biol. chem, 243, p3558 (1968).
[0360] The term "amino acid" refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function in a manner similar to naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, such as hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refer to compounds that have the same basic chemical structure as naturally occurring amino acids (i.e., an alpha carbon bound to a hydrogen, a carboxyl group, an amino group, and an R group), such as homoserine, norleucine, methionine sulfoxide, and methionine methylsulfonium. Such analogs have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as naturally occurring amino acids. Amino acid mimetics refer to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but function in a manner similar to naturally occurring amino acids.
[0361] The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), full-length antibodies, and antibody fragments (or antigen-binding fragments, or antigen-binding portions), so long as they exhibit the desired antigen-binding activity.
[0362] "Native antibodies" refer to naturally occurring immunoglobulin molecules. For example, natural IgG antibodies are heterotetrameric glycoproteins of approximately 150,000 daltons, composed of two identical light chains and two identical heavy chains bound by disulfide bonds. From the N- to the C-terminus, each heavy chain has a variable region (VH), also known as a variable heavy domain, or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from the N- to the C-terminus, each light chain has a variable region (VL), also known as a variable light domain, or a light chain variable domain, followed by a constant light domain (also known as a light chain constant region, CL).
[0363] The terms "full-length antibody," "intact antibody," and "whole antibody" are used interchangeably herein to refer to an antibody that comprises a structure substantially similar to a native antibody structure, or whose heavy chains contain an Fc region as defined herein.
[0364] An "isolated" antibody is one that has been separated from the components of its natural environment. In the present disclosure, in some embodiments, the antibodies can be purified to a purity greater than 90% or 99%. In some embodiments, the antibodies are purified and assayed by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC).
[0365] The terms "variable region" or "variable domain" or "variable domain" refer to the domains of an antibody's heavy and / or light chains involved in antigen binding. Natural IgG antibodies, VH and VL, each contain four conserved framework regions (FRs) and three complementarity-determining regions (CDRs). The terms "complementarity-determining regions" or "CDRs" refer to the regions within the variable domain that primarily contribute to antigen binding; "framework" or "FRs" refers to the variable domain residues excluding the CDR residues. VHs contain three CDR regions: HCDR1, HCDR2, and HCDR3; VLs contain three CDR regions: LCDR1, LCDR2, and LCDR3. Each VH and VL is composed of three CDRs and four FRs, arranged from amino-terminus to carboxyl-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. A single VH or VL may be sufficient to confer antigen-binding specificity.
[0366] The boundaries of the amino acid sequence of the CDR can be determined by various well-known schemes, for example: "Kabat" numbering rule (see Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th edition, Public Health Service, National Institutes of Health, Bethesda, MD), "Chothia" numbering rule, "ABM" numbering rule, "contact" numbering rule (see Martin, ACR. Protein Sequence and Structure Analysis of Antibody Variable Domains [J]. 2001) and ImMunoGenTics (IMGT) numbering rule (Lefranc, MP et al., Dev. Comp. Immunol., 27, 55-77 (2003); Front Immunol. 2018 Oct 16; 9: 2278), etc.; the correspondence between various numbering systems is well known to those skilled in the art, and is exemplified as shown in Table 1 below.
[0367] Table 1. Relationships between CDR numbering systems
[0368] The term "light chain" includes a variable region domain VL and a constant region domain CL. VL is at the amino terminus of the light chain. Light chains include kappa chains and lambda chains.
[0369] The term "heavy chain" includes the variable region domain VH and three constant region domains CHI, CH2, and CH3. The VH domain is located at the amino terminus of the heavy chain, and the CH domain is located at the carboxyl terminus, with CH3 closest to the carboxyl terminus of the polypeptide. The heavy chain can be of any isotype, including IgG (including IgG1, IgG2, IgG3, and IgG4 subtypes), IgA (including IgA1 and IgA2 subtypes), IgM, and IgE.
[0370] The term "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, single-domain antibodies, single-chain Fab (scFab), diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv); and multispecific antibodies formed from antibody fragments.
[0371] The term "Fc region" or "fragment crystallizable region" is used to define the C-terminal region of an antibody heavy chain, including native sequence Fc regions and engineered Fc regions. In some embodiments, the Fc region of a human IgG heavy chain is defined as extending from the amino acid residue at position Cys226 or from Pro230 to its carboxyl terminus. The boundaries of the Fc region of an antibody heavy chain can also vary, such as by deleting the C-terminal lysine in the Fc region (residue 447 according to the EU numbering system) or deleting the C-terminal glycine and lysine in the Fc region (residues 446 and 447 according to the EU numbering system). Therefore, in some embodiments, the composition of a complete antibody can include an antibody population in which all K447 residues and / or G446+K447 residues have been removed. In some embodiments, the composition of a complete antibody can include an antibody population in which K447 residues and / or G446+K447 residues have not been removed. In some embodiments, the composition of a complete antibody has an antibody population with and without a mixture of antibodies containing K447 residues and / or G446+K447 residues. Suitable native sequence Fc regions for use in the antibodies described herein include human IgG1, IgG2 (IgG2A, IgG2B), IgG3, and IgG4. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also known as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
[0372] The term "chimeric antibody" refers to an antibody in which a portion of the heavy and / or light chains is derived from a particular source or species, while the remainder of the heavy and / or light chains is derived from a different source or species.
[0373] The term "humanized antibody" is an antibody that retains the reactivity of a non-human antibody while having lower immunogenicity in humans. For example, this can be achieved by retaining the non-human CDR regions and replacing the rest of the antibody with their human counterparts (i.e., the constant region and the framework region portion of the variable region).
[0374] The term "human antibody" means an antibody whose variable and constant regions are human sequences. The term encompasses antibodies that are derived from human genes but have, for example, sequences that have been altered to reduce potential immunogenicity, increase affinity, eliminate cysteine or glycosylation sites that may cause undesirable folding. The term encompasses antibodies recombinantly produced in non-human cells (which may confer glycosylation that is not characteristic of human cells). The term also encompasses antibodies that have been raised in transgenic mice containing some or all human immunoglobulin heavy and light chain loci. The meaning of human antibody explicitly excludes humanized antibodies that contain non-human antigen-binding residues.
[0375] The term "affinity matured" refers to an antibody that has one or more alterations in one or more CDRs of the antibody that result in an improvement in the antibody's affinity for the antigen compared to the parent antibody. In some embodiments, affinity matured antibodies will have nanomolar or even picomolar affinities for the target antigen. Affinity matured antibodies can be generated by methods known in the art. Marks et al., Bio / Technology 10:779-783 (1992) describe affinity maturation by VH and VL domain shuffling. Random mutagenesis of CDR and / or framework residues is described in Barbas et al., PNAS, 91:3809-3813 (1994); Schier et al., Gene 169:147-155 (1995); Yelton et al., J. Immunol. 155:1994-2004 (1995); Jackson et al., J. Immunol. 154(7):3310-9 (1995) and Hawkins et al., J. Mol. Biol. 226:889-896 (1992).
[0376] The term "monoclonal antibody" refers to a group of substantially homogeneous antibodies, i.e., the amino acid sequence of the antibody molecules included in the group is identical, except for the natural mutations that may be present in a small amount. In contrast, polyclonal antibody preparations are generally included in a variety of different antibodies with different amino acid sequences in their variable domains, which are generally specific for different epitopes. "Monoclonal" represents the characteristic of the antibody obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring the production of antibodies by any ad hoc method. For example, monoclonal antibodies can be prepared by the hybridoma method described by Kohler et al., (1975) Nature 256:495, or by recombinant DNA methods (see, for example, U.S. Patent number 4,816,567). Alternatively, "monoclonal antibodies" can be isolated from phage antibody libraries using the technology described in Clackson et al., (1991) Nature 352:624-628 and Marks et al., (1991) J. Mol. Biol. 222:581-597. See also Presta (2005) J. Allergy Clin. Immunol. 116:731, or methods for producing "monoclonal antibodies" using transgenic animals containing all or part of the human immunoglobulin loci.
[0377] The term "antigen" refers to a molecule or portion of a molecule that can be selectively bound by an antibody and that can be used in an animal to produce antibodies that can bind to the antigen. An antigen may have one or more epitopes that can interact with different antibodies.
[0378] The term "epitope" refers to an area or region on an antigen that is capable of specific binding to an antibody. An epitope can be formed by a continuous string of amino acids (linear epitope) or comprise non-contiguous amino acids (conformational epitope), for example, brought into spatial proximity by folding of the antigen (i.e., by tertiary folding of the antigen in the case of proteinaceous properties). Conformational epitopes differ from linear epitopes in that antibody binding to a conformational epitope is lost in the presence of denaturing solvents. An epitope comprises at least 3, at least 4, at least 5, at least 6, at least 7, or 8-10 amino acids in a unique spatial conformation.
[0379] Screening for antibodies that bind to a specific epitope (i.e., those that bind to the same epitope) can be performed using methods well known in the art, including but not limited to: alanine scanning, peptide blotting (see Meth. Mol. Biol. 248 (2004) 443-463), peptide cleavage analysis, epitope excision, epitope extraction, chemical modification of antigens (see Prot. Sci. 9 (2000) 487-496), and cross-blocking (see "Antibodies", Harlow and Lane (Cold Spring Harbor Press, Cold Spring Harb., NY)).
[0380] An "antibody that binds to the same epitope as a reference antibody" or an "antibody that competes for binding" with a reference antibody refers to an antibody that blocks the binding of the reference antibody to the antigen by 50% or more in a competition assay, or an antibody whose binding to the antigen is blocked by the reference antibody by 50% or more. As another example, to determine whether a test antibody binds to the same epitope as a reference antibody, the reference antibody is allowed to bind to the antigen under saturating conditions. After removing excess reference antibody, the ability of the test antibody to bind to the antigen is assessed. To confirm whether the test antibody binds to the same epitope or is merely hindered by steric factors, conventional experiments can be used (e.g., peptide mutations and binding analysis using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antibody binding assay available in the art). This assay should be performed in two settings, i.e., both antibodies are used as saturating antibodies. If, in both settings, only the first (saturating) antibody is able to bind to the antigen, it can be concluded that the test antibody and the reference antibody compete for binding to the antigen.
[0381] In some embodiments, two antibodies are considered to bind to the same or overlapping epitope if a 1-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antibody inhibits the binding of the other antibody by at least 50%, at least 75%, at least 90%, or even 99% or more, as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 50 (1990) 1495-1502).
[0382] In some embodiments, two antibodies are considered to bind to the "same epitope" if substantially all of the amino acid mutations in the antigen that reduce or eliminate binding of one antibody reduce or eliminate binding of the other antibody; and two antibodies are considered to have "overlapping epitopes" if only a portion of the amino acid mutations in the antigen reduce or eliminate binding of the other antibody.
[0383] The term "affinity" refers to the overall strength of the non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding ligand (e.g., an antigen). Unless otherwise indicated, as used herein, binding "affinity" refers to internal binding affinity, which reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its ligand Y can generally be represented by an equilibrium dissociation constant (KD). Affinity can be measured by conventional methods known in the art, including those described herein.
[0384] As used herein, the term "kassoc" or "ka" refers to the association rate of a specific antibody-antigen interaction, and the term "kdis" or "kd" refers to the dissociation rate of a specific antibody-antigen interaction. The term "KD" refers to the equilibrium dissociation constant, which is obtained from the ratio of kd to ka (i.e., kd / ka) and is expressed as a molar concentration (M). The KD value of an antibody can be measured using methods well known in the art. For example, a biosensor system such as a system measures surface plasmon resonance, or affinity in solution is measured by solution equilibrium titration (SET).
[0385] The terms "specifically bind," "specific binding," or "binding" refer to antibodies that bind to an antigen or an epitope within the antigen with a higher affinity than they bind to other antigens or epitopes. Typically, antibodies bind to an antigen with an affinity of about 1×10 -7 M or less (e.g., about 1×10 -8 M or smaller, approximately 1×10 -9 The antibody binds to the antigen or an epitope within the antigen with an equilibrium dissociation constant (KD) of 1 M or less. In some embodiments, the KD of the antibody binding to the antigen is 10% or less (e.g., 1%) of the KD of the antibody binding to a nonspecific antigen (e.g., BSA, casein). KD can be measured using methods known in the art, for example, by Surface plasmon resonance assay. However, an antibody that specifically binds to an antigen or an epitope within an antigen may have cross-reactivity to other related antigens, for example, to corresponding antigens from other species (homologous), such as humans or monkeys, e.g., Macaca fascicularis (cynomolgus, cyno), chimpanzee (Pan troglodytes (chimpanzee, chimp), or marmoset (Callithrix jacchus (common marmoset, marmoset).
[0386] The terms "anti-TF antibody" and "antibody that binds to TF" refer to an antibody that is capable of binding to TF with sufficient affinity. In certain embodiments, the antibody that binds to the anti-TF antibody has an equilibrium dissociation constant (KD) of < about 1 μM, < about 100 nM, < about 10 nM, < about 1 nM, < about 0.1 nM, < about 0.01 nM, or < about 0.001 nM (e.g., 10 -8 M or smaller, such as 10 -8 M to 10 -9 M, for example 10 -9 M or less). In certain embodiments, the anti-TF antibody binds to a TF epitope that is conserved among TF from different species.
[0387] The term "antibody-dependent cell-mediated cytotoxicity" or "ADCC" refers to a form of cytotoxicity in which secreted Ig binds to Fc receptors (FcRs) on certain cytotoxic cells (e.g., natural killer (NK) cells, neutrophils, and macrophages), allowing these cytotoxic effector cells to specifically bind to target cells bearing antigens and subsequently kill the target cells with cytotoxins. Antibodies "arm" cytotoxic cells and are necessary for such killing. NK cells, the main cells that mediate ADCC, express only FcγRIII, while monocytes express FcγRI, FcγRII, and FcγRIII. FcR expression on hematopoietic cells is summarized in Ravetch and Kinet, Annu. Rev. Immunol. 9:457-92 (1991), Table 3 on page 464. To assess the ADCC activity of the target molecule, an in vitro ADCC assay can be performed, using analytical methods such as those described in U.S. Patent Nos. 5,500,362 or 5,821,337. Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively, the ADCC activity of the antibody of interest can also be assessed in vivo, for example, in an animal model (such as that disclosed in Clynes et al., (USA) 95: 652-656 (1998)).
[0388] The term "antibody-dependent cellular phagocytosis" ("ADCP") refers to a mechanism by which antibody-coated target cells are eliminated by internalization by phagocytes, such as macrophages or dendritic cells.
[0389] The term "complement-dependent cytotoxicity" or "CDC" refers to a mechanism of cell death in which the Fc effector domain of a target-binding antibody binds to and activates the complement component C1q, which in turn activates the complement cascade, leading to target cell death. Activation of complement can also result in the deposition of complement components on the surface of target cells, which promote CDC by binding to complement receptors (e.g., CR3) on leukocytes.
[0390] The term "nucleic acid" is used interchangeably with the term "polynucleotide" herein and refers to deoxyribonucleotides or ribonucleotides and polymers thereof in single-stranded or double-stranded form. The term encompasses nucleic acids containing known nucleotide analogs or modified backbone residues or linkages that are synthetic, naturally occurring, and non-naturally occurring, have similar binding properties to reference nucleic acids, and are metabolized in a manner similar to reference nucleotides. Examples of such analogs include, but are not limited to, phosphorothioates, phosphoramidates, methylphosphonates, chiral-methylphosphonates, 2-O-methyl ribonucleotides, peptide-nucleic acids (PNAs). An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from the components of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. A "nucleic acid encoding an anti-TF antibody" refers to one or more nucleic acid molecules encoding the antibody heavy and light chains (or fragments thereof).
[0391] Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences as well as the explicitly indicated sequence. Specifically, as described in detail below, degenerate codon substitutions can be obtained by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081, 1991; Ohtsuka et al., J. Biol. Chem. 260:2605-2608, 1985; and Rossolini et al., Mol. Cell. Probes 8:91-98, 1994).
[0392] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer of amino acid residues. The term applies to amino acid polymers in which one or more amino acid residues is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers and non-naturally occurring amino acid polymers.
[0393] The term "naked antibody" refers to an antibody that is not conjugated to a heterologous moiety (eg, a cytotoxic moiety) or a radiolabel. Naked antibodies can be present in pharmaceutical formulations.
[0394] The terms "identity", "sequence identity" or "amino acid sequence identity" refer to the degree (percentage) to which the amino acids / nucleic acids of two sequences are identical at equivalent positions when the two sequences are optimally aligned (introducing gaps, if necessary, to achieve the maximum sequence identity percentage, and not considering any conservative substitutions as part of the sequence identity). To determine the percentage of sequence identity, alignment can be achieved by a variety of methods well known in the art, such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR). One skilled in the art can determine the parameters suitable for measuring alignment, including any algorithm required to achieve maximum alignment over the full length of the compared sequences.
[0395] The term "conservatively modified variant" or "conservative substitution" refers to replacing an amino acid in a protein with another amino acid having similar characteristics (e.g., charge, side chain size, hydrophilicity / hydrophobicity, backbone structure and rigidity, etc.), such that such changes can generally be made without altering the biological activity of the protein. It is understood by those skilled in the art that, generally, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson et al., (1987) Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224 (4th Ed.)). The term "conservatively modified variant" when applied to nucleic acid sequences refers to nucleic acids that encode the same or substantially the same amino acid sequence, or, where the nucleic acid does not encode an amino acid sequence, to substantially the same sequence. Due to the degeneracy of the genetic code, any given protein can be encoded by multiple functionally identical nucleic acids. For example, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at each position where a codon specifies an alanine, the codon can be changed to any of the corresponding codons described without changing the encoded polypeptide. Such nucleic acid variations are "silent variations," which are one type of conservatively modified variation. Each nucleic acid sequence encoding a polypeptide herein also describes each possible silent variation of the nucleic acid. One skilled in the art will recognize that each codon in a nucleic acid (except AUG, which is generally the only codon for methionine; and TGG, which is generally the only codon for tryptophan) can be modified to produce functionally identical molecules. Thus, each silent variation of a nucleic acid encoding a polypeptide is implicit in each described sequence.
[0396] The term "expression vector" or "expression construct" refers to a vector suitable for transforming a host cell and containing a nucleic acid sequence that directs and / or controls (along with the host cell) the expression of one or more heterologous coding regions operably linked thereto. An expression construct may include, but is not limited to, sequences that affect or control transcription, translation, and, when introns are present, RNA splicing of the coding region operably linked thereto.
[0397] As used herein, "operably linked" refers to a relationship in which the components to which the term is applied allow them to perform their inherent functions under appropriate conditions. For example, a control sequence in an expression vector that is "operably linked" to a protein coding sequence is linked thereto so as to achieve expression of the protein coding sequence under conditions compatible with the transcriptional activity of the control sequence.
[0398] The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may not be completely identical to the parent cell in nucleic acid content and may contain mutations. Mutant progeny having the same function or biological activity as screened or selected for in the initial transformed cell are included herein. Host cells include prokaryotic and eukaryotic host cells, wherein eukaryotic host cells include, but are not limited to, mammalian cells, insect cell lines, plant cells, and fungal cells. Exemplary host cells are as follows: Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells and HEK-293 cells, Pichia pastoris, Pichia finlandica, Candida albicans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei.
[0399] As used in this disclosure, the expressions "cell," "cell line," and "cell culture" are used interchangeably and include the progeny of such cells. Thus, the terms "transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom, regardless of the number of passages. It should also be understood that not all progeny have exactly the same DNA content due to sense or nonsense mutations. Mutant progeny that have the same function or biological activity as the original transformed cell from which they were selected are included.
[0400] Methods for producing and purifying antibodies and antigen-binding fragments are well known in the art, such as those described in Chapters 5-8 and 15 of the Cold Spring Harbor Laboratory Manual of Antibody Laboratory Techniques. The disclosed antibodies or antigen-binding fragments utilize genetic engineering methods to add one or more human FR regions to non-human CDR regions. Human FR germline sequences can be obtained from the ImMunoGeneTics (IMGT) website (http: / / imgt.cines.fr) by comparing them with the IMGT Human Antibody Variable Region Germline Gene Database and MOE software, or from the Journal of Immunoglobulins, 2001, ISBN 012441351.
[0401] The engineered antibodies or antigen-binding fragments disclosed herein can be prepared and purified using conventional methods. For example, cDNA sequences encoding heavy and light chains can be cloned and recombined into expression vectors. The recombinant immunoglobulin expression vector can be stably transfected into host cells. As a more recommended existing technology, mammalian expression systems will lead to glycosylation of antibodies, especially at the N-terminal site of the Fc region. Stable clones are obtained by expressing antibodies that specifically bind to human TF. Positive clones are expanded in culture medium in a bioreactor to produce antibodies. The culture medium that secretes antibodies can be purified using conventional techniques. For example, purification can be performed using A or G Sepharose FF columns. Non-specifically bound components are washed away. The bound antibodies are then eluted using a pH gradient method, and the antibody fragments are detected by SDS-PAGE and collected. The antibodies can be filtered and concentrated using conventional methods. Soluble mixtures and polymers can also be removed using conventional methods, such as molecular sieves and ion exchange. The obtained product should be immediately frozen, such as at -70°C, or freeze-dried.
[0402] "Isolated" refers to a purified state and, in this context, means that the specified molecule is substantially free of other biomolecules, such as nucleic acids, proteins, lipids, carbohydrates, or other materials, such as cell debris and growth medium. Generally, the term "isolated" is not intended to imply the complete absence of such materials or the absence of water, buffers, or salts, unless they are present in amounts that significantly interfere with experimental or therapeutic uses of the compounds as described herein.
[0403] The term "drug" refers to a chemical substance that can alter or identify physiological functions and pathological states of the body and can be used to prevent, diagnose, and treat disease. Drugs include cytotoxic drugs. There is no strict distinction between drugs and poisons. Poisons are chemical substances that can have toxic effects on the body at relatively low doses, potentially damaging human health. Excessive doses of any drug can produce toxic reactions.
[0404] The term "cytotoxic drugs" refers to substances that inhibit or prevent cell function and / or cause cell death or destruction. In principle, cytotoxic drugs can kill tumor cells at sufficiently high concentrations. However, due to their lack of specificity, they can also cause apoptosis of normal cells while killing tumor cells, leading to serious side effects. Cytotoxic drugs include toxins, such as small molecule toxins or enzyme-active toxins of bacterial, fungal, plant or animal origin, radioactive isotopes (such as At 211 , I 131 , I 125 、Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 and radioactive isotopes of Lu), chemotherapeutic drugs, antibiotics, and nucleolytic enzymes.
[0405] The term "alkyl" refers to a saturated aliphatic hydrocarbon group, which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, and more preferably an alkyl group containing 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-Dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2,2-diethylpentyl, n-decyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and various branched-chain isomers thereof. More preferred are lower alkyl groups containing 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, and the like. The alkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably independently selected from one or more substituents selected from D atoms, halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0406] The term "alkoxy" refers to -O-(alkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy include methoxy, ethoxy, propoxy, butoxy. Alkoxy groups may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more of the following groups independently selected from D atoms, halogen, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0407] The term "alkylene" refers to a saturated straight or branched aliphatic hydrocarbon group, which is a residue derived from the removal of two hydrogen atoms from the same carbon atom or two different carbon atoms of a parent alkane, and is a straight or branched group containing 1 to 20 carbon atoms, preferably 1 to 12 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably 1 to 6 carbon atoms. Non-limiting examples of alkylene include, but are not limited to, methylene (-CH2-), 1,1-ethylene (-CH(CH3)-), 1,2-ethylene (-CH2CH2)-, 1,1-propylene (-CH(CH2CH3)-), 1,2-propylene (-CH2CH(CH3)-), 1,3-propylene (-CH2CH2CH2-), 1,4-butylene (-CH2CH2CH2CH2-), and the like. The alkylene group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably independently selected from one or more substituents of alkenyl, alkynyl, alkoxy, haloalkoxy, cycloalkyloxy, heterocyclyloxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo.
[0408] The term "alkenyl" refers to an alkyl compound containing at least one carbon-carbon double bond in a molecule, wherein the definition of alkyl is as described above. Preferably, the alkenyl contains 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably the alkenyl contains 2 to 6 carbon atoms. Alkenyl can be substituted or unsubstituted, and when substituted, substituent is preferably one or more following groups, independently selected from one or more substituents in alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0409] The term "alkynyl" refers to an alkyl compound containing at least one carbon-carbon triple bond in a molecule, wherein the definition of alkyl is as described above. Preferably, the alkynyl contains 2 to 12 (e.g., 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, and 12) carbon atoms, more preferably the alkynyl contains 2 to 6 carbon atoms. Alkynyl can be substituted or unsubstituted, and when substituted, the substituent is preferably one or more of the following groups, independently selected from one or more substituents in alkyl, alkoxy, halogen, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxyl, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl, and heteroaryl.
[0410] The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic hydrocarbon substituent, wherein the cycloalkyl ring contains 3 to 20 carbon atoms, preferably 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) carbon atoms, preferably 3 to 8 carbon atoms, more preferably 3 to 6 carbon atoms (e.g., C 3-6 Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, and cyclooctyl; and polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups.
[0411] The term " spiroalkyl " refers to 5 to 20 yuan, a polycyclic group sharing a carbon atom (claiming spiral atom) between monocycles, which can contain one or more double bonds. Preferably, it is 6 to 14 yuan (for example, 6, 7, 8, 9, 10, 11, 12, 13 and 14), more preferably 7 to 10 yuan (for example, 7, 8, 9 or 10 yuan). According to the number of shared spiral atoms between ring and ring, spiroalkyl is divided into single spiroalkyl, double spiroalkyl or multiple spiroalkyl, preferably single spiroalkyl and double spiroalkyl. More preferably, it is 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan and 6 yuan / 6 yuan single spiroalkyl. The non-limiting examples of spiroalkyl include:
[0412] Term " fused cycloalkyl " refers to 5 to 20 yuan, and each ring in the system shares the full carbon polycyclic group of a pair of carbon atoms adjacent to other rings in the system, and wherein one or more rings can contain one or more double bonds.Preferably 6 to 14 yuan (for example 6,7,8,9,10,11,12,13 and 14), more preferably 7 to 10 yuan (for example 7,8,9 or 10 yuan).Can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl according to the number of composition ring, preferably bicyclic or tricyclic, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan and 6 yuan / 6 yuan bicyclic alkyl.The non-limiting example of fused cycloalkyl includes:
[0413] The term "bridged cycloalkyl" refers to a 5 to 20-membered, all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected, and which may contain one or more double bonds. Preferably, it is 6 to 14 members (e.g., 6, 7, 8, 9, 10, 11, 12, 13, and 14), more preferably 7 to 10 members (e.g., 7, 8, 9, or 10 members). Depending on the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic, or polycyclic bridged cycloalkyl groups, preferably bicyclic, tricyclic, or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged cycloalkyl groups include:
[0414] The cycloalkyl ring includes a cycloalkyl group as described above (including a monocyclic, spirocyclic, condensed and bridged ring) fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl group, non-limiting examples of which include indanyl, tetrahydronaphthyl and benzocycloheptanyl, etc.; preferably indanyl and tetrahydronaphthyl.
[0415] The cycloalkyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably independently selected from one or more substituents of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0416] The term "heterocyclyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic substituent containing 3 to 20 ring atoms, one or more of which is a heteroatom selected from nitrogen, oxygen, sulfur, S(O) or S(O)2, but excluding the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, it contains 3 to 12 (e.g., 3, 4, 5, 6, 7, 8, 9, 10, 11 and 12) ring atoms, of which 1 to 4 (e.g., 1, 2, 3 and 4) are heteroatoms; more preferably, it contains 3 to 8 (e.g., 3, 4, 5, 6, 7 and 8) ring atoms, of which 1 to 3 are heteroatoms (e.g., 1, 2 and 3); more preferably, it contains 3 to 6 ring atoms, of which 1 to 3 are heteroatoms; and most preferably, it contains 5 or 6 ring atoms, of which 1 to 3 are heteroatoms. Non-limiting examples of monocyclic heterocyclic groups include pyrrolidinyl, tetrahydropyranyl, 1,2,3,6-tetrahydropyridinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, etc. Polycyclic heterocyclic groups include spiro, fused, and bridged heterocyclic groups.
[0417] The term "spiro heterocyclic radical" refers to a polycyclic heterocyclic group of 5 to 20 members, one atom (called spiral atom) shared between the monocycles, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, S (O) or S (O) 2, and the remaining ring atoms are carbon. It may contain one or more double bonds. It is preferably 6 to 14 members, more preferably 7 to 10 members (e.g., 7, 8, 9 or 10 members). According to the number of shared spiral atoms between the rings, the spiro heterocyclic radical is divided into a monospiro heterocyclic radical, a dispiro heterocyclic radical or a polyspiro heterocyclic radical, preferably a monospiro heterocyclic radical and a dispiro heterocyclic radical. It is more preferably 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan or 6 yuan / 6 yuan monospiro heterocyclic radical. Non-limiting examples of spiro heterocyclic radicals include:
[0418] The term "fused heterocyclic radical" refers to 5 to 20 yuan, and each ring in the system shares a polycyclic heterocyclic group of a pair of atoms adjacent to other rings in the system, and one or more rings can contain one or more double bonds, wherein one or more annular atoms are selected from nitrogen, oxygen, sulphur, S (O) or S (O) 2 heteroatoms, and the remaining annular atoms are carbon.Preferably 6 to 14 yuan, more preferably 7 to 10 yuan (such as 7, 8, 9 or 10 yuan).According to the number of the composition ring, bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic radicals can be divided into, preferably bicyclic or tricyclic, more preferably 3 yuan / 4 yuan, 3 yuan / 5 yuan, 3 yuan / 6 yuan, 4 yuan / 4 yuan, 4 yuan / 5 yuan, 4 yuan / 6 yuan, 5 yuan / 4 yuan, 5 yuan / 5 yuan, 5 yuan / 6 yuan, 6 yuan / 3 yuan, 6 yuan / 4 yuan, 6 yuan / 5 yuan and 6 yuan / 6 yuan bicyclic fused heterocyclic radicals.The non-limiting examples of fused heterocyclic radicals include:
[0419] The term "bridged heterocyclic group" refers to a polycyclic heterocyclic group of 5 to 14 members, wherein any two rings share two atoms that are not directly connected, which may contain one or more double bonds, wherein one or more ring atoms are heteroatoms selected from nitrogen, oxygen, sulfur, S(O) or S(O)2, and the remaining ring atoms are carbon. Preferably, it is 6 to 14 members, more preferably 7 to 10 members (e.g., 7, 8, 9 or 10 members). According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
[0420] The heterocyclyl ring includes a heterocyclyl as described above (including monocyclic, spiro heterocyclic, fused heterocyclic and bridged heterocyclic rings) fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, non-limiting examples of which include:
[0421] wait.
[0422] The heterocyclyl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment. The substituent is preferably independently selected from one or more substituents of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0423] The term "aryl" refers to a 6- to 14-membered all-carbon monocyclic or fused polycyclic (fused polycyclic is a ring that shares adjacent pairs of carbon atoms) group having a conjugated π electron system, preferably 6- to 10-membered, such as phenyl and naphthyl. The aryl ring includes an aryl ring as described above fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring, non-limiting examples of which include:
[0424] The aryl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably independently selected from one or more substituents of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0425] The term "heteroaryl" refers to a heteroaromatic system containing 1 to 4 heteroatoms (e.g., 1, 2, 3, and 4), 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur, and nitrogen. Heteroaryl is preferably 5 to 10-membered (e.g., 5, 6, 7, 8, 9, or 10-membered), more preferably 5-membered or 6-membered, such as furyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyridazinyl, imidazolyl, pyrazolyl, triazolyl, and tetrazolyl. The heteroaryl ring includes a heteroaryl fused to an aryl, heterocyclyl, or cycloalkyl ring as described above, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples of which include:
[0426] The heteroaryl group may be substituted or unsubstituted. When substituted, the substituent may be substituted at any available point of attachment, and the substituent is preferably independently selected from one or more substituents of halogen, alkyl, alkoxy, haloalkyl, haloalkoxy, cycloalkyloxy, heterocyclyloxy, hydroxy, hydroxyalkyl, cyano, amino, nitro, cycloalkyl, heterocyclyl, aryl and heteroaryl.
[0427] The cycloalkyl, heterocyclyl, aryl and heteroaryl groups mentioned above include residues derived by removing one hydrogen atom from a parent ring atom, or residues derived by removing two hydrogen atoms from the same ring atom or two different ring atoms of the parent, i.e., "divalent cycloalkyl", "divalent heterocyclyl", "arylene" or "heteroarylene".
[0428] The term "amino-protecting group" is used to protect the amino group with a readily removable group, so that the amino group remains unchanged while other parts of the molecule undergo reactions. Non-limiting examples include (trimethylsilyl)ethoxymethyl, tetrahydropyranyl, tert-butyloxycarbonyl (Boc), acetyl, benzyl, allyl, p-methoxybenzyl, and tert-butyldimethylsilyl (TBS). These groups may optionally be substituted with 1-3 substituents selected from halogen, alkoxy, or nitro.
[0429] The term "hydroxy protecting group" refers to a hydroxy derivative that is usually used to block or protect the hydroxy group while reacting on other functional groups of the compound. As an example, preferably, the hydroxy protecting group can be (C 1-10 alkyl or aryl) 3 silyl, for example: triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl (TBS) and tert-butyldiphenylsilyl, etc.; can be C 1-10 Alkyl or substituted alkyl, preferably alkoxy or aryl substituted alkyl, more preferably C 1-6 Alkoxy-substituted C 1-6 Alkyl or phenyl substituted C 1-6 Alkyl, most preferably C 1-4 Alkoxy-substituted C 1-4Alkyl, for example: methyl, tert-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl and 2-tetrahydropyranyl (THP), etc.; can be (C 1-10 Alkyl or aromatic) acyl, such as formyl, acetyl, benzoyl and p-nitrobenzoyl, etc.; can be (C 1-6 alkyl or 6 to 10 membered aryl) sulfonyl; can also be (C 1-6 alkoxy or 6- to 10-membered aryloxy)carbonyl.
[0430] The term "cycloalkyloxy" refers to a cycloalkyl-O- group in which cycloalkyl is as defined above.
[0431] The term "heterocyclyloxy" refers to a heterocyclyl-O- group in which heterocyclyl is as defined above.
[0432] The term "alkylthio" refers to an alkyl-S- group in which alkyl is as defined above.
[0433] The term "haloalkyl" refers to an alkyl group substituted with one or more halogens, wherein alkyl is as defined above.
[0434] The term "haloalkoxy" refers to an alkoxy group substituted with one or more halogens, wherein alkoxy is as defined above.
[0435] The term "deuterated alkyl" refers to an alkyl group substituted with one or more deuterium atoms, wherein alkyl is as defined above.
[0436] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxy groups, wherein alkyl is as defined above.
[0437] The term "halogen" refers to fluorine, chlorine, bromine or iodine.
[0438] The term "hydroxy" refers to -OH.
[0439] The term "mercapto" refers to -SH.
[0440] The term "amino" refers to -NH2.
[0441] The term "cyano" refers to -CN.
[0442] The term "nitro" refers to -NO2.
[0443] The term "oxo" refers to "=0".
[0444] The term "carbonyl" refers to C=O.
[0445] The term "carboxy" refers to -C(O)OH.
[0446] The term "carboxylate" refers to -C(O)O(alkyl), -C(O)O(cycloalkyl), (alkyl)C(O)O-, or (cycloalkyl)C(O)O-, where alkyl and cycloalkyl are as defined above.
[0447] The term "antibody-drug conjugate (ADC)" refers to a drug that is linked to an antibody via a linker unit and a biologically active cytotoxin or a small molecule drug with cell-killing activity.
[0448] The antibodies or antibody fragments described herein can be coupled to effector molecules by any means. For example, the antibodies or antibody fragments can be attached to the cytotoxic drug by chemical or recombinant means. Chemical methods for preparing fusions or conjugates are known in the art and can be used to prepare immunoconjugates. The method for coupling the antibody or antibody fragment and the drug must be able to connect the antibody and the cytotoxic drug without interfering with the ability of the antibody or antibody fragment to bind to the target molecule.
[0449] In one embodiment, the antibody and the cytotoxic drug are both proteins and can be coupled using technology well known in the art. There are hundreds of cross-linking agents disclosed in the art that can couple two proteins. The cross-linking agent is generally selected based on the reactive functional groups available or inserted on the antibody or cytotoxic drug. In addition, if there is no reactive group, a photoactivatable cross-linking agent can be used. In some cases, it may be necessary to include a spacer between the antibody and the cytotoxic drug. Cross-linking agents known in the art include homobifunctional agents: glutaraldehyde, dimethyl adipimidate and bis(diazobenzidine), and heterobifunctional agents: m-maleimidobenzoyl-N-hydroxysuccinimide and sulfo-m-maleimidobenzoyl-N-hydroxysuccinimide.
[0450] Cross-linking agents that can be used to couple effector molecules to antibody fragments include, for example, TPCH (S-(2-thiopyridyl)-L-cysteine hydrazide) and TPMPH (S-(2-thiopyridyl)mercapto-propionyl hydrazide). TPCH and TPMPH react with carbohydrate moieties of glycoproteins that have previously been oxidized by mild periodate treatment, thereby forming a hydrazone bond between the hydrazide portion of the cross-linker and the aldehyde generated by the periodate. The heterobifunctional cross-linkers GMBS (N-(γ-maleimidobutyryloxy)-succinimide) and SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane) react with primary amines to introduce a maleimido group onto the component. This maleimido group can then react with a sulfhydryl group on another component that can be introduced by the cross-linker, thereby forming a stable thioether bond between the components. If steric hindrance between the components interferes with the activity of any one component, a cross-linking agent can be used to introduce a long spacer arm between the components, such as succinimidyl 3-(2-pyridyldithio) propionate (SPDP). Thus, there are many suitable cross-linking agents that can be used and each is selected based on its effect on the optimal immunoconjugate yield.
[0451] The term "drug loading", also known as the drug-to-antibody ratio (DAR), is the average number of drugs conjugated to each antibody in the ADC. It can be, for example, in the range of about 1 to about 10 drugs conjugated to each antibody, and in certain embodiments, in the range of about 1 to about 8 drugs conjugated to each antibody, preferably in the range of 2-8, 2-7, 2-6, 2-5, 2-4, 3-4, 3-5, 4-8, 5-6, 5-7, 5-8 and 6-8. Exemplary, the drug loading can be an average of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10. The ADC formula disclosed herein includes a collection of antibody-drug conjugates within the aforementioned range. In embodiments of the present disclosure, the drug loading can be expressed as n, which is a decimal or integer. The drug loading can be determined by conventional methods such as UV / visible spectroscopy, mass spectrometry, ELISA assay and HPLC.
[0452] The term "linker unit" or "connection fragment" or "connection unit" refers to a chemical structure fragment or bond that is connected to an antibody or its antigen-binding fragment at one end and to a drug at the other end, and can also be connected to other linkers before being connected to the drug.
[0453] The term "joint" can include one or more joint components. Exemplary joint components include 6-maleimidocaproyl ("MC"), maleimidopropionyl ("MP"), valine-citrulline ("val-cit" or "vc"), alanine-phenylalanine ("ala-phe"), p-aminobenzyloxycarbonyl ("PAB"), and those derived from coupling with joint reagents: N-succinimidyl 4-(2-pyridylthio) valerate ("SPP"), N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1 carboxylate ("SMCC", also referred to herein as "MCC") and N-succinimidyl (4-iodo-acetyl) aminobenzoate ("SIAB"). The joint can include an extender, a spacer, and an amino acid unit, and can be synthesized by methods known in the art, such as those described in US2005-0238649A1. The joint can be a "cleavable joint" for facilitating drug release in cells. For example, an acid-labile linker (e.g., a hydrazone), a protease-sensitive (e.g., a peptidase-sensitive) linker, a photolabile linker, a dimethyl linker, or a disulfide-containing linker (Chari et al., Cancer Research 52:127-131 (1992); U.S. Pat. No. 5,208,020) can be used.
[0454] Connector components include but are not limited to:
[0455] MC=6-maleimidocaproyl, the structure is as follows:
[0456] Val-Cit or "vc" = valine-citrulline (an exemplary dipeptide in a protease-cleavable linker),
[0457] Citrulline = 2-amino-5-ureidopentanic acid,
[0458] The PAB group is p-aminobenzyloxycarbonyl (an example of a "self-immolative" linker component) and has the following structure:
[0459] Me-Val-Cit = N-methyl-valine-citrulline (wherein the linker peptide bond has been modified to protect it from cleavage by cathepsin B),
[0460] MC(PEG)6-OH = Maleimidocaproyl-polyethylene glycol (can be attached to antibody cysteines),
[0461] SPP = N-succinimidyl 4-(2-pyridylthio)pentanoate,
[0462] SPDP = N-succinimidyl 3-(2-pyridyldithio) propionate,
[0463] SMCC = succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate,
[0464] IT=iminothiolane,
[0465] In one embodiment of the present disclosure, the cytotoxic drug is coupled to the sulfhydryl group of the antibody via a linker unit.
[0466] The loading capacity of the ligand drug conjugate can be controlled by the following non-limiting methods, including:
[0467] (1) Control the molar ratio of the compound linker and the monoclonal antibody,
[0468] (2) Control reaction time and temperature,
[0469] (3) Select different reaction reagents.
[0470] The term "optionally" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur. For example, "C 1-6 The term "alkyl" means that halogen or cyano may but need not be present, and the description includes both the case where the alkyl is substituted by halogen or cyano and the case where the alkyl is not substituted by halogen and cyano.
[0471] The term "substituted" refers to a group in which one or more hydrogen atoms, preferably 1 to 6, more preferably 1 to 3, are independently replaced by a corresponding number of substituents. Those skilled in the art will be able to determine (by experiment or theory) without undue effort which substitutions are possible or impossible. For example, an amino or hydroxyl group with free hydrogens may be unstable when combined with a carbon atom with an unsaturated (e.g., olefinic) bond.
[0472] The concentration of the antibody-drug conjugate in the present disclosure is based on the concentration of the protein, that is, the concentration of the antibody portion in the antibody-drug conjugate.
[0473] With respect to a drug or pharmacologically active agent, the term "therapeutically effective amount" refers to a non-toxic amount of the drug or agent sufficient to achieve the desired effect. The determination of an effective amount varies from person to person, depending on the age and general condition of the recipient, as well as the specific active agent. The appropriate effective amount in each individual case can be determined by those skilled in the art through routine experimentation.
[0474] The compounds and intermediates disclosed herein can also exist in different tautomeric forms, and all such forms are included within the scope of the disclosure. The term "tautomer" or "tautomeric form" refers to structural isomers of different energies that can interconvert via a low energy barrier. For example, proton tautomers (also referred to as prototransfer tautomers) include interconversions via proton migration, such as keto-enol and imine-enamine, lactam-lactim isomerization. The lactam-lactim equilibrium example is between A and B as shown below.
[0475] All compounds in this disclosure can be drawn as either Form A or Form B. All tautomeric forms are within the scope of this disclosure. The naming of the compounds does not exclude any tautomers.
[0476] The term "pharmaceutically acceptable" as used herein refers to compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of subjects without excessive toxicity, irritation, allergic response or other problems or complications, commensurate with a reasonable benefit / risk ratio, and effective for the intended use.
[0477] The preparation of conventional pharmaceutical compositions can be found in the Chinese Pharmacopoeia.
[0478] As used herein, the singular form "a," "an," and "the" include plural references and vice versa unless the context clearly dictates otherwise.
[0479] "About" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. In the context of a particular assay, result, or embodiment, unless expressly stated otherwise in the examples or elsewhere in the specification, "about" means within one standard deviation according to customary practice in the art.
[0480] The term "pharmaceutically acceptable carrier" or "pharmaceutically acceptable carrier" refers to a component of a pharmaceutical formulation that is different from the active ingredient and is non-toxic to the subject. Pharmaceutically acceptable carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.
[0481] The term "subject" or "individual" includes humans and non-human animals. Non-human animals include all vertebrates (e.g., mammals and non-mammals) such as non-human primates (e.g., cynomolgus monkeys), sheep, dogs, cows, chickens, amphibians, and reptiles. Unless otherwise indicated, the terms "patient" or "subject" are used interchangeably herein. As used herein, the term "cynomolgus monkey" or "cynomolgus monkey" refers to cynomolgus monkeys (Macaca fascicularis). In certain embodiments, the individual or subject is a human.
[0482] The term "excipient" refers to any additive in a pharmaceutical preparation other than the main drug, also known as an adjuvant. Examples include binders, fillers, disintegrants, and lubricants in tablets; the base component of semisolid ointments and creams; and preservatives, antioxidants, flavoring agents, fragrances, cosolvents, emulsifiers, solubilizers, osmotic pressure regulators, and colorants in liquid preparations.
[0483] The term "diluent," also known as filler, primarily increases the weight and volume of a tablet. The addition of a diluent not only maintains a certain volume but also reduces dosage variations of the main ingredient and improves the drug's compressibility. When the tablet contains an oily component, an absorbent is added to absorb the oil and maintain a "dry" state, facilitating tablet production. Examples include starch, lactose, inorganic calcium salts, and microcrystalline cellulose.
[0484] The term "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically / pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically / pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.
[0485] The pharmaceutical composition may be in the form of a sterile injectable aqueous solution. Acceptable vehicles and solvents that may be used include water, Ringer's solution, and isotonic sodium chloride solution. The sterile injectable formulation may be a sterile injectable oil-in-water microemulsion in which the active ingredient is dissolved in an oil phase. For example, the active ingredient is dissolved in a mixture of soybean oil and lecithin. The oil solution is then added to a mixture of water and glycerol to form a microemulsion. The injection or microemulsion may be injected into the subject's bloodstream via local bolus injection. Alternatively, the solution or microemulsion may be administered in a manner that maintains a constant circulating concentration of the disclosed compound. To maintain such a constant concentration, a continuous intravenous drug delivery device may be used. An example of such a device is the Deltec CADD-PLUS™ 5400 intravenous pump.
[0486] The pharmaceutical composition can be in the form of a sterile injection water or oil suspension for intramuscular and subcutaneous administration. The suspension can be prepared according to known techniques using the above-mentioned suitable dispersants or wetting agents and suspending agents. Sterile injection preparations can also be sterile injection solutions or suspensions prepared in non-toxic parenteral acceptable diluents or solvents, such as solutions prepared in 1,3-butanediol. In addition, sterile fixed oils can be conveniently used as solvents or suspension media. For this purpose, any blended fixed oil including synthetic mono- or diglycerides can be used. In addition, fatty acids such as oleic acid can also be used to prepare injections.
[0487] "Administering" or "administering," as it applies to an animal, human, experimental subject, cell, tissue, organ or biological fluid, refers to the contact of an exogenous drug, therapeutic agent, diagnostic agent or composition with the animal, human, subject, cell, tissue, organ or biological fluid.
[0488] The term "sample" refers to a collection of similar fluids, cells, or tissues isolated from a subject, as well as fluids, cells, or tissues present in a subject. Exemplary samples are biological fluids such as blood, serum and serosal fluid, plasma, lymph, urine, saliva, cystic fluid, tears, feces, sputum, mucosal secretions of secretory tissues and organs, vaginal secretions, ascites, pleura, pericardium, peritoneum, fluids of the abdominal cavity and other body cavities, fluids collected by bronchial lavage, synovial fluid, liquid solutions in contact with a subject or biological source, such as cell and organ culture media (including cell or organ conditioned media), lavage fluids, etc., tissue biopsy samples, fine needle aspirations, surgically resected tissues, organ cultures, or cell cultures.
[0489] The term "pharmaceutically acceptable salt" or "pharmaceutically usable salt" refers to a salt of the antibody-drug conjugates of the present disclosure, or a salt of a compound described in the present disclosure, which salt is safe and effective when used in mammals and has the desired biological activity. The antibody-drug conjugates of the present disclosure contain at least one amino group and can therefore form salts with acids.
[0490] "Treatment" (and grammatical variations thereof) refers to clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed for prevention or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing the occurrence or recurrence of disease, alleviating symptoms, alleviating / reducing any direct or indirect pathological consequences of the disease, preventing metastasis, reducing the rate of disease progression, improving or alleviating the disease state, and regression or improved prognosis. In some embodiments, the antibodies of the present disclosure are used to delay the development of disease or slow the progression of disease.
[0491] "Effective amount" is generally enough to reduce the severity and / or frequency of symptoms, eliminate these symptoms and / or potential causes, prevent symptoms and / or their potential causes from occurring and / or improve or ameliorate the damage (e.g., lung disease) caused by or associated with the disease state. In some embodiments, an effective amount is a therapeutically effective amount or a prophylactic effective amount. A "therapeutically effective amount" is enough to treat a disease state or symptom, particularly a state or symptom associated with the disease state, or otherwise prevent, hinder, delay or reverse the disease state or any other undesirable symptom associated with the disease in any way. A "prophylactic effective amount" is an amount that will have a predetermined preventive effect when administered to a subject, such as preventing or delaying the onset (or recurrence) of the disease state, or reducing the likelihood of the onset (or recurrence) of the disease state or associated symptoms. Complete treatment or prevention may not occur after administering one dose, but may occur after administering a series of doses. Thus, a therapeutically or prophylactically effective amount can be administered in one or more doses. A "therapeutically effective amount" and a "prophylactically effective amount" may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of the therapeutic agent or combination of therapeutic agents to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic agent or combination of therapeutic agents include, for example, improved health status in the subject.
[0492] The details of one or more embodiments of the present disclosure are set forth in the above description. Other features, objects and advantages of the present disclosure will be apparent from the description and claims. In the description and claims, unless the context clearly indicates otherwise, the singular includes the case of plural referents. Unless otherwise defined, all technical and scientific terms used herein have the common meaning understood by those of ordinary skill in the art to which the present disclosure belongs. All patents and publications cited in the description are incorporated by reference. The following examples are presented to more fully illustrate the preferred embodiments of the present disclosure. These examples should not be construed in any way to limit the scope of the present disclosure, which is defined by the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0493] FIG1 shows the results of binding of the antibodies disclosed herein to mouse TF antigen protein.
[0494] FIG2 shows the results of binding of the antibodies disclosed herein to rat TF antigen protein.
[0495] FIG3 shows the results of PT detection of ADC-1 disclosed herein in a pharmacokinetic experiment in cynomolgus monkeys.
[0496] FIG4 shows the results of APTT detection of ADC-1 disclosed herein in a pharmacokinetic experiment in cynomolgus monkeys. DETAILED DESCRIPTION
[0497] The following embodiments are used to further describe the present disclosure, but these embodiments are not intended to limit the scope of the present disclosure.
[0498] Experimental methods in the Examples or Test Examples disclosed herein, where specific conditions are not specified, generally followed conventional conditions or those recommended by the raw material or product manufacturer. See Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory; and Contemporary Methods in Molecular Biology, Ausubel et al., Greene Publishing Associates, Wiley Interscience, NY. Reagents whose sources are not specified were commercially available. This disclosure incorporates the entire contents of application WO2020063676 A1.
[0499] Example
[0500] Example 1: Cloning and construction of antigens and antibodies
[0501] Antibody (including light and heavy chains) and antigen molecular clones were constructed using overlap extension PCR or gene synthesis methods known in the art. Antibody and protein antigen sequences were constructed into pTT5 vectors and cloned using Expi293F. TM Cells (A14528, Gibco) were transfected to obtain the corresponding antibodies and antigen proteins.
[0502] Antigen protein sequence
[0503] The human TF (hTF) protein sequence was obtained from NCBI (AAA61151.1), and its extracellular domain (ECD) consists of 219 amino acids (Ser33-Glu251). The monkey TF (cyno TF, cTF) protein sequence was obtained from NCBI (XP_005542723.1), and its extracellular domain (ECD) consists of 220 amino acids (Ser33-Glu252). The rat TF (rTF) protein sequence was obtained from NCBI (AAA16966.1), and its extracellular domain (ECD) consists of 224 amino acids (Ala29-Glu252). The mouse TF (mTF) protein sequence was obtained from UniProtKB (P20352), and its extracellular domain (ECD) consists of 223 amino acids (Ala29-Glu251). The TF extracellular region sequence may be tagged with a His or human Fc region (hFc) or mouse Fc region (mFc).
[0504] The plasmids involved in the proteins used in TF immunity and detection were prepared using pTT5 vectors or ExpiFectamine TM The plasmid was transfected into Expi293F using 293 transfection kit (A14525, Gibco).TM cells to obtain the target protein.
[0505] The antigen protein sequence is as follows:
[0506] Human TF full sequence:
[0507] Cyno TF full sequence:
[0508] Rat TF full sequence:
[0509] Mouse TF full sequence:
[0510] Human TF ECD-His sequence (hTF-his):
[0511] Human TF ECD-hFc sequence (hTF-hFc):
[0512] cyno TF ECD-hFc sequence (cTF-hFc):
[0513] Cyno TF ECD-His sequence (cTF-his):
[0514] cyno TF ECD-mFc sequence (cTF-mFc):
[0515] Rat TF ECD-His sequence:
[0516] Mouse TF ECD-His sequence:
[0517] The human-rat hybrid antigen, HuRatTF, was constructed by combining amino acids 1-130 of rat TF (Met1-Ala130) with amino acids 130-245 of human TF (Pro130-Glu245) and adding a His tag. Several amino acids that affect coagulation were replaced with Ala, and several positions in the rat TF sequence were mutated to the corresponding human TF sequences. The protein sequence (including the signal peptide) is as follows:
[0518] Note: The italics represent the human TF sequence, the dotted line represents the signal peptide, the double underline represents the mutation of the rat TF amino acid to the corresponding human TF amino acid, the underline represents the mutation of the site affecting coagulation to alanine Ala, and the wavy line represents the His tag.
[0519] Sequences used to construct antigen cell lines
[0520] The plasmids involved in the antigen cell lines used for TF immunization and detection were prepared with reference to Cell, 01Aug 2005, 122(3):473-48. The piggyBac transposon plasmid containing the antigen sequence was transfected into NIH / 3T3 (ATCC, CRL-1658) or / and CHO-K1 (ATCC, CCL-61) cells using Lipofectamine 3000 transfection reagent (Invitrogen, L3000015) and transposase hyPBase plasmid, and the cells were sorted by flow cytometry (BD FACSAria TM The target cell line was obtained using a Fusion Cell Sorter. The antigen sequence used to construct the cell line consists of the full-length TF antigen, the self-cleaving protein (2A), and the green fluorescent protein (EGFP) sequence. The details are as follows:
[0521] piggyBac transposon plasmid components (PB 3'LTR and PB 5'LTR, NCBI-KF658273.1):
[0522] PB 3'LTR-CMV promoter-antigen sequence-beta-globin poly(A)-PB 5'LTR-Ampicillin resisitance gene-bla promoter
[0523] Transposase hyPBase plasmid components (hyPBase, NCBI-OL519599.1):
[0524] EF1a promoter-hyPBase-BGH polyA-f1 origin-SV40 early promoter and origin-Neomycin resistance gene-SV40 polyA-pUC origin-Ampicillin resisitance gene-bla promoter
[0525] Human TF-2A-EGFP sequence (hTF):
[0526] Cyno TF-2A-EGFP sequence (cTF):
[0527] Note: The italicized text is the TF sequence, the double underlined text is the 2A sequence, and the wavy line is the EGFP sequence.
[0528] Referring to patent WO2010066803A2, seven human-mouse chimeric antigens were prepared by replacing a segment of the human TF sequence with the corresponding sequence of mouse TF: hTF1 (1-41 mm), hTF2 (42-84 mm), hTF3 (85-122 mm), hTF4 (123-137 mm), hTF7 (138-184 mm), hTF5 (185-225 mm), and hTF6 (226-250 mm). These seven antigens are referred to as hTF1, hTF2, hTF3, hTF4, hTF7, hTF5, and hTF6. Of these, hTF7 was not mentioned in patent WO2010066803A2 and is newly added to this disclosure. The human TF epitopes corresponding to these seven antigens in the test examples are shown in Table 2.
[0529] Table 2
[0530] The 7 chimeric antigen sequences are as follows:
[0531] hTF1 (1-41mm) sequence:
[0532] hTF2 (42-84mm) sequence:
[0533] hTF3 (85-122mm):
[0534] hTF4 (123-137mm):
[0535] hTF7 (138-184 mm):
[0536] hTF5 (185-225mm):
[0537] hTF6 (226-250mm):
[0538] Note: The italicized text indicates the human TF sequence, the underlined text indicates the mouse TF sequence, the double underlined text indicates the 2A sequence, and the wavy line indicates the EGFP sequence.
[0539] Epitope analysis was performed by FACS binding experiments, and the antibodies disclosed herein bind to a specific epitope of TF.
[0540] Positive control antibody sequence
[0541] The positive control TF011 antibody sequence is derived from the monoclonal antibody sequence of tisotumab vedotin, the H39 antibody variable region sequence is derived from WO2018036117A1, and the 10H10 antibody variable region sequence is derived from WO2012125559A1.
[0542] TF011 antibody heavy chain sequence (tisotumab vedotin monoclonal antibody sequence):
[0543] TF011 antibody light chain sequence (tisotumab vedotin monoclonal antibody sequence):
[0544] H39 antibody heavy chain sequence (variable region + human IgG1 constant region):
[0545] H39 antibody light chain sequence (variable region + human kappa constant region):
[0546] 10H10 antibody heavy chain sequence (variable region + human IgG1 constant region):
[0547] 10H10 antibody light chain sequence (variable region + human kappa constant region):
[0548] TF011-mIgG2a heavy chain sequence (variable region + mouse mIgG2a constant region):
[0549] TF011-mκ light chain sequence (variable region + mouse κ constant region):
[0550] Negative control antibody hIgG1 (VH / VL derived from C25 antibody of patent US6114143A):
[0551] Amino acid sequence of hIgG1 antibody heavy chain (C25 heavy chain variable region + human IgG1 constant region):
[0552] Amino acid sequence of hIgG1 antibody light chain (C25 light chain variable region + human kappa constant region):
[0553] Note: The underlined part is the variable region sequence.
[0554] Example 2: Purification of antigen protein and antibody protein
[0555] His-tagged antigens were affinity purified using a 25 mL Ni Sepharose Excel column (GE Healthcare, 17-3712-01). Fc-tagged antigens or antibodies were affinity purified using a 25 mL ProteinA-MabSelect SuRe column (GE Healthcare, 17-5438-01). The affinity-purified proteins were then subjected to size-exclusion chromatography to remove aggregates or cleavage fragments. The specific methods are as follows:
[0556] Nickel column purification: Use PBS solution to wash the balanced nickel column, centrifuge the supernatant after cell transfection to remove impurities and then load the sample. 280 When the reading drops to the baseline, rinse the nickel column with PBS solution containing 10 mM imidazole to remove non-specifically bound proteins, then elute the target protein with PBS solution containing 300 mM imidazole, collect the elution peak liquid, and exchange the liquid into PBS for storage.
[0557] Chromatographic exclusion purification: rinse the equilibrated SEC column (GE, superdex75) with PBS solution, load the protein obtained by nickel column purification or Protein A purification (load volume ≤ 3% column volume), elute with PBS solution as the mobile phase, collect the elution peaks, and identify the component where the target protein is located by SDS-PAGE.
[0558] Affinity chromatography of antibody or Fc fusion protein: After cell transfection, the supernatant was centrifuged at high speed to remove impurities and then loaded onto the Protein A column. 280 When the readings dropped to baseline, the target protein was eluted with 100 mM acetic acid, pH 3.5. The eluate was neutralized with 1 M Tris-HCl, pH 8.0, and the solution was exchanged into PBS. If necessary, gel chromatography (Superdex200, GE) was used to further remove aggregates.
[0559] Example 3: Preparation of anti-human TF monoclonal antibody
[0560] 3.1 Immunity
[0561] Anti-human TF monoclonal antibodies were obtained using hybridoma technology. Female SJL white mice, 6-8 weeks old (Shanghai Slake Laboratory Animal Co., Ltd., Animal Production License No. SCXK(Shanghai)2017-0005) were used in this experiment. Mice were housed in an SPF-grade laboratory environment for one week under a 12 / 12 hr light / dark cycle, a temperature of 20-25°C, and a humidity of 40-60%. Acclimated mice were immunized according to the following protocol.
[0562] 3.2 Immunization regimen
[0563] The immune antigens of anti-human TF antibody 67 are hTF-NIH / 3T3 cells (SEQ ID NO: 12), cTF-NIH / 3T3 cells (SEQ ID NO: 13), hTF-his protein (SEQ ID NO: 5) and cTF-mFc protein (SEQ ID NO: 106). The immunization method is cell and protein immunization. The first immunization uses hTF-NIH / 3T3 cells. Before immunization, the cells are pre-treated with Gold Adjuvant (Sigma, T2684) 0.1 mL / mouse was injected intraperitoneally. Half an hour later, each mouse was intraperitoneally injected with 0.1 mL of normal saline diluted to 10 8 On day 14, the second immunization was performed using cTF-NIH / 3T3 cells, and each mouse was intraperitoneally injected with 0.1 mL of saline diluted to 10 8 The third immunization was performed on day 35, using hTF-his protein, 50 μg / animal / time, antigen and adjuvant ( The fourth immunization was conducted on day 49 with hTF-his protein at a ratio of 1:1 and antigen and adjuvant ( The mice were vaccinated with a 1:1 ratio of antigen and adjuvant (Gold Adjuvant). Blood was collected on days 29, 47, and 61, and serum antibody titers were determined using ELISA and FACS. After the fourth immunization, mice with high serum antibody titers that plateaued were selected for splenocyte fusion. Three days before splenocyte fusion, a booster immunization was performed with an intraperitoneal (ip) injection of 50 μg / mouse of a 1:1 mixture of hTF-his and cTF-mFc in saline.
[0564] Anti-human TF antibody 310 immunization antigens are hTF-NIH / 3T3 cells, cTF-NIH / 3T3 cells, hTF-CHO-K1 cells and cTF-CHO-K1 cells, and the immunization method is cell-based immunization. The first immunization uses hTF-NIH / 3T3 cells. Before immunization, Gold Adjuvant 0.1 mL / mouse was injected intraperitoneally. Half an hour later, each mouse was injected intraperitoneally with 0.1 mL of normal saline diluted to 10 8 On day 59, the second immunization was performed using cTF-NIH / 3T3 cells, and each mouse was intraperitoneally injected with 0.1 mL of saline diluted to 10 8 On day 74, the third immunization was performed using hTF-CHO-K1 cells. Each mouse was intraperitoneally injected with 0.1 mL of saline diluted to 10 8 On day 90, the fourth immunization was performed using cTF-CHO-K1 cells, and each mouse was intraperitoneally injected with 0.1 mL of saline diluted to 10 8 On day 104, the fifth immunization was performed using hTF-CHO-K1 cells. Each mouse was intraperitoneally injected with 0.1 mL of saline diluted to 10 8 Cells were suspended at 100 cells / mL. Blood was collected on days 68, 85, and 118, and serum antibody titers were determined using ELISA and FACS. After the fifth immunization, mice with high serum antibody titers that had plateaued were selected for spleen cell fusion. Three days before spleen cell fusion, a booster immunization was performed with an intraperitoneal (ip) injection of 50 μg / mouse of a 1:1 mixture of hTF-his (SEQ ID NO: 5) and cTF-his (SEQ ID NO: 8) in saline.
[0565] 3.3 Spleen cell fusion
[0566] The spleen lymphocytes were electrofused with myeloma cells Sp2 / 0-Ag14 cells (ATCC, CRL-8287 TM ) were fused to obtain hybridoma cells. Hybridoma cells were cultured at a rate of 3-4×10 5 Resuspend cells at a density of 100 μL / well in complete culture medium (IMDM medium containing 20% FBS, 1× HAT, and 1× OPI) at a density of 100 μL / well and seed into a 96-well cell culture plate. Incubate at 37°C, 5% CO₂ for 3-4 days, remove the supernatant, add 200 μL / well of HT complete culture medium (IMDM medium containing 20% FBS, 1× HAT, and 1× OPI), and incubate at 37°C, 5% CO₂ for 3-5 days before testing.
[0567] 3.4 Hybridoma Cell Screening
[0568] Once the hybridoma cell density reaches 90%, the cell supernatant is removed and primary screening is performed in a 96-well plate using a cell-based ELISA assay. Positive wells are then transferred to a 24-well plate. After 2-3 days, when the cell density reaches 90%, the cell supernatant is removed and rescreened in the 24-well plate using FACS and / or competition and / or coagulation assays. Cells from a single well are subcloned to obtain a single cell clone. The supernatant of the subcloned cells is collected and retested. Hybridoma clones obtained through the above screening assays are used for subsequent experiments.
[0569] Example 4: Determination of amino acid sequence of mouse monoclonal antibody variable region
[0570] The hybridoma monoclonal cell line obtained in Example 3 was subjected to variable region amino acid sequence determination. The mouse hybridoma variable region sequence and the human constant region sequence were combined to form a human-mouse chimeric antibody (CHAb) sequence, and the chimeric antibody was expressed and identified. The specific method is as follows:
[0571] First, total RNA of hybridoma monoclonal cell lines was obtained by conventional methods, and then reverse transcription kit PrimeScript TM cDNA was prepared using IV 1st strand cDNA Synthesis Mix (TAKARA, 6215A). PCR was performed using the cDNA as a template to amplify PCR fragments containing the light and heavy chain variable regions. The corresponding variable region sequences were obtained by sequencing the PCR fragments. The resulting light and heavy chain sequences were cloned into the pTT5 vector using conventional methods, and recombinant monoclonal antibodies were expressed and their activity was verified.
[0572] The amino acid residues of the VH / VL CDRs of the anti-human TF antibody were determined and annotated using the Kabat numbering system.
[0573] Sequence of mouse hybridoma monoclonal antibody 67#:
[0574] 67# Heavy chain variable region:
[0575] 67# light chain variable region:
[0576] Sequence of mouse hybridoma monoclonal antibody 310#:
[0577] 310# Heavy chain variable region:
[0578] 310# light chain variable region:
[0579] Table 3. CDRs of 67# mouse antibody
[0580] Table 4. CDRs of 310# mouse antibody
[0581] Human IgG1 heavy chain constant region:
[0582] Human kappa light chain constant region:
[0583] The heavy chain sequence and light chain sequence of the chimeric antibody CH67 are as follows:
[0584] CH67 heavy chain:
[0585] CH67 light chain:
[0586] The heavy chain sequence and light chain sequence of the chimeric antibody CH310 are as follows:
[0587] CH310 heavy chain:
[0588] CH310 light chain:
[0589] Example 5: Humanization of anti-human TF antibody 310#
[0590] Using MOE software, we compared the heavy and light chain variable region germline genes with the IMGT human antibody heavy and light chain variable region database. We selected heavy and light chain variable region germline genes with high homology to 310# as templates. The CDRs of this murine antibody were transplanted into the corresponding human templates, resulting in a variable region sequence with the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. For example, the CDR amino acid residues in the following specific examples are identified and annotated using the Kabat numbering system.
[0591] The humanized antibody #310 uses the FR1, FR2, FR3 of IGKV4-1*01 or IGKV1-33*01, and the FR4 of IGKJ4*01 as the light chain framework region template; the FR1, FR2, FR3 of IGHV1-46*01, and the FR4 of IGHJ6*01 as the heavy chain framework region template. Optionally, amino acid residues 1, 9, 10, 31, 43, 67, and / or 73 of the light chain variable region of the humanized antibody are substituted; and / or amino acid residues 1, 28, 69, 71, 73, 76, and / or 78 of the heavy chain variable region of the humanized antibody are substituted.
[0592] Table 5. Humanized design of 310#
[0593] Note: For example, D1S means that according to the Kabat numbering system, D at position 1 is mutated to S, and so on.
[0594] Table 6. CDRs of humanized antibody #310
[0595] The heavy chain variable region sequence and light chain variable region sequence of humanized antibody #310 are as follows:
[0596] >hu310-VH1:
[0597] >hu310-VH2:
[0598] >hu310-VL1:
[0599] >hu310-VL2:
[0600] >hu310-VL3:
[0601] >hu310-VL4:
[0602] >hu310-VL5:
[0603] >hu310-VL6:
[0604] >hu310-VL7:
[0605] >hu310-VL8:
[0606] Note: In the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4; the underlined part is the CDR sequence determined according to the Kabat numbering system; the non-underlined part is the FR sequence; the double-underlined bold part is the amino acid point mutation.
[0607] The heavy chain variable region and light chain variable region of humanized antibody #310 were recombined with the human heavy chain IgG1 constant region (SEQ ID NO: 54) and the human light chain kappa constant region (SEQ ID NO: 55), respectively, to obtain the humanized antibodies shown in Table 7 below.
[0608] Table 7. Humanized Antibody #310
[0609] The heavy chain and light chain sequences of humanized antibody #310 are as follows:
[0610] hu310-1 / hu310-2 / hu310-3 / hu310-4 / hu310-5 / hu310-6 / hu310-7 / hu310-8 heavy chain:
[0611] hu310-9 / hu310-10 / hu310-11 / hu310-12 / hu310-13 / hu310-14 / hu310-15 / hu310-16 heavy chain:
[0612] hu310-1 / hu310-9 light chain:
[0613] hu310-2 / hu310-10 light chain:
[0614] hu310-3 / hu310-11 light chain:
[0615] hu310-4 / hu310-12 light chain:
[0616] hu310-5 / hu310-13 light chain:
[0617] hu310-6 / hu310-14 light chain:
[0618] hu310-7 / hu310-15 light chain:
[0619] hu310-8 / hu310-16 light chain:
[0620] Example 6: Humanization of anti-human TF antibody 67#
[0621] The light and heavy chain sequences of the murine anti-TF monoclonal antibody 67# obtained in Example 4 were compared for homology with the IMGT human antibody heavy and light chain variable region germline gene database using MOE software. The heavy and light chain variable region germline genes with high homology to 67# were selected as templates. The CDRs of this murine antibody were transplanted into the corresponding human templates, forming a variable region sequence with the order FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. For example, in the following specific examples, the CDR amino acid residues are identified and annotated using the Kabat numbering system.
[0622] The human germline light chain template for antibody #67 is selected from FR1, FR2, FR3 of IGKV4-1*01 or IGKV1-33*01, and FR4 of IGKJ4*01; the human germline heavy chain template is selected from FR1, FR2, FR3 of IGHV2-26*01 or IGHV4-30-4*01, and FR4 of IGHJ6*01. Optionally, amino acid residues at positions 8, 9, 10, 43, and / or 73 of the light chain variable region of the humanized antibody are substituted; and / or amino acid residues at positions 1, 6, 16, 27, 29, 30, 42, 44, 49, 71, 73, 76, 78, and / or 81 of the heavy chain variable region of the humanized antibody are substituted.
[0623] Table 8. Humanized design of 67#
[0624] Note: G42R means that the G at position 42 was mutated back to R according to the Kabat numbering system.
[0625] The heavy chain variable region and light chain variable region sequences of humanized antibody #67 are as follows:
[0626] >hu67-VH1:
[0627] >hu67-VH2:
[0628] >hu67-VH3:
[0629] >hu67-VH4:
[0630] >67VL-VL1:
[0631] >67VL-VL2:
[0632] >67VL-VL3:
[0633] >67VL-VL4:
[0634] Note: In the above sequence, the order is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4; the underlined part is the CDR sequence determined according to the Kabat numbering system; the non-underlined part is the FR sequence; the double-underlined bold part is the amino acid point mutation.
[0635] The heavy chain variable region and light chain variable region of humanized antibody #67 were recombined with the human heavy chain IgG1 constant region (SEQ ID NO: 54) and the human light chain Kappa constant region (SEQ ID NO: 55), respectively, to obtain the humanized antibodies shown in Table 9 below.
[0636] Table 9. Humanized Antibody #67
[0637] The heavy chain and light chain sequences of the humanized antibody are as follows:
[0638] hu67-1 / hu67-5 / hu67-9 / hu67-13 heavy chain sequence:
[0639] hu67-2 / hu67-6 / hu67-10 / hu67-14 heavy chain sequence:
[0640] hu67-3 / hu67-7 / hu67-11 / hu67-15 heavy chain sequence:
[0641] hu67-4 / hu67-8 / hu67-12 / hu67-16 heavy chain sequences:
[0642] hu67-1 / hu67-2 / hu67-3 / hu67-4 light chain sequence:
[0643] hu67-5 / hu67-6 / hu67-7 / hu67-8 light chain sequence:
[0644] hu67-9 / hu67-10 / hu67-11 / hu67-12 light chain sequence:
[0645] hu67-13 / hu67-14 / hu67-15 / hu67-16 light chain sequences:
[0646] Example 7: hu67-11 affinity maturation
[0647] The humanized anti-TF monoclonal antibody hu67-11 obtained in Example 6 was used to construct an antibody yeast library using hTF-hFc (SEQ ID NO: 6) and cTF-hFc (SEQ ID NO: 7) as antigens for affinity maturation to enhance the cell binding ability of the target antibody. The optimal humanized antibody was selected by cloning, expressing, purifying, and testing these antibodies.
[0648] 7.1 Construction of affinity maturation yeast library and screening of the library
[0649] To obtain better anti-TF hu67-11-related antibodies, hu67-11 was affinity matured using yeast display platform technology. Based on hu67-11-scFv (SEQ ID NO: 171), an affinity mature yeast library targeting human TF and monkey TF binding CDRs was designed and prepared, and new mutants were screened from it.
[0650] Construction of yeast library: Degenerate primers were designed and the designed mutant amino acids were introduced into the hu67-11-scFv mutant library by PCR. The size of each library was 10 9 The constructed yeast library was then verified for diversity by next-generation sequencing.
[0651] In the first round of screening, yeast from the hu67-11-scFv mutant library were incubated with biotinylated hTF-hFc protein in 50 mL of phosphate-buffered saline (PBSA) containing 0.1% bovine serum albumin (BSA) for 1 hour at room temperature. The mixture was then washed three times with PBSA to remove unbound antibody fragments. Streptavidin microbeads (Millienvi Biotec, Auburn, CA) were then added to the mutant library bound to the biotinylated hTF-hFc protein and loaded onto an AutoMACS system for sorting. Antibodies with high affinity for human TF were harvested and cultured for expansion. Expression in these cultures was then induced. The resulting enriched library was then screened for binding to biotinylated cTF-hFc (SEQ ID NO: 7) in a second round.
[0652] For the third and fourth rounds of screening, the library cells from the previous round were incubated with biotinylated hTF-hFc and Mouse Anti-cMyc (9E10, Sigma) antibodies in PBSA for 1 hour at room temperature. The mixture was washed three times with BSA to remove unbound antibody fragments. Goat anti-mouse-Alexa 488 (Life technologies, A-11001) and Strepavidin-PE (Life technologies, S-866) were added and incubated at 4°C for 1 hour. The mixture was washed three times with PBSA to remove unbound antibody fragments. Finally, high-affinity antibodies were screened by FACS (BD FACSAria™ FUSION).
[0653] The mutant library was screened using biotinylated TF-hFc antigen for 2-3 rounds of MACS screening (streptavidin magnetic beads, Invitrogen) and 2-3 rounds of FACS screening (BD FACSAria™ FUSION). Approximately 600 yeast clones were selected for culture and induced expression. FACS (BD FACSCanto II) was used to test the binding of yeast clones to the hTF-hFc (SEQ ID NO: 6) and cTF-hFc (SEQ ID NO: 7). Yeast clones with higher affinity than the wild-type (hu67-11-scfv) were selected for sequencing verification. Sequenced clones were then aligned and analyzed. After removing redundant sequences, the non-redundant sequences were converted to full-length human IgG for expression in mammalian cells.
[0654] hu67-11-scFv sequence:
[0655] Example 8: Modification of hu67-11 affinity maturation molecule
[0656] The humanized antibody hu67-11 obtained in Example 7 was subjected to CDR point mutations (single and / or combined), and a P40S point mutation was introduced into the FR region to further enhance cell binding. Cloning, expression, purification, and testing of these antibodies revealed variable region sequences of antibodies hu67Y116 and hu67Y118 with further enhanced cell binding.
[0657] Antibody hu67Y116 / hu67Y118 heavy chain variable region sequence:
[0658] Antibody hu67Y116 light chain variable region sequence:
[0659] Antibody hu67Y118 light chain variable region sequence:
[0660] Table 10. CDRs of antibody hu67Y116
[0661] Table 11. CDRs of antibody hu67Y118
[0662] hu67Y116 / hu67Y118 heavy chain sequence:
[0663] hu67Y116 light chain sequence:
[0664] hu67Y118 light chain sequence:
[0665] Example 9: 10H10 molecular sequence modification
[0666] Antibody 10H10 does not affect coagulation, as confirmed by crystal structure analysis (Cellular Signaling 36(2017)139-144). After homology comparison within an antibody database, a humanized antibody model was constructed. Back mutations were selected based on the model, and the CDR regions were optimized. The antibody was cloned, expressed, purified, and tested.
[0667] The human germline light chain template for antibody 10H10 is selected from FR1, FR2, FR3 of IGKV1-39*01, and FR4 of IGKJ2*01, and the human germline heavy chain template is FR1, FR2, FR3 of IGHV1-46*01 or IGHV7-4-1*02, and FR4 of IGHJ1*01. Optionally, amino acid residues at positions 24, 25, 27b, 27d, 27f, 56, and / or 97 of the light chain variable region of the humanized antibody are substituted; and / or amino acid residues at positions 1, 26, 27, 30, 31, 38, 40, 53, 54, 56, 57, 67, 68, 69, 71, 81, and / or 101 of the heavy chain variable region of the humanized antibody are substituted.
[0668] Table 12. Humanized design of antibody 10H10
[0669] Note: The amino acid positions in the table are numbered according to Kabat. L27bI means that the L at position 27b is mutated to I according to the Kabat numbering system. The same applies below.
[0670] The obtained sequence of the variable region of the hu10H10 humanized antibody is as follows:
[0671] hu10H10 VH1(SEQ ID NO:84)
[0672] hu10H10 VH2(SEQ ID NO:85)
[0673] hu10H10 VH3(SEQ ID NO:86)
[0674] hu10H10 VH4(SEQ ID NO:87)
[0675] hu10H10 VH5(SEQ ID NO:88)
[0676] hu10H10 VH6(SEQ ID NO:89)
[0677] hu10H10 VH7(SEQ ID NO:90)
[0678] hu10H10 VH8(SEQ ID NO:91)
[0679] hu10H10 VH9(SEQ ID NO:92)
[0680] hu10H10 VH10(SEQ ID NO:93)
[0681] hu10H10 VH11(SEQ ID NO:71)
[0682] hu10H10 VH12(SEQ ID NO:94)
[0683] hu10H10 VH13(SEQ ID NO:95)
[0684] hu10H10 VH14(SEQ ID NO:96)
[0685] hu10H10 VL1(SEQ ID NO:97)
[0686] hu10H10 VL2 (SEQ ID NO:98)
[0687] hu10H10 VL3 (SEQ ID NO:99)
[0688] hu10H10 VL4 (SEQ ID NO: 100)
[0689] hu10H10 VL5 (SEQ ID NO: 101)
[0690] hu10H10 VL6 (SEQ ID NO: 102)
[0691] hu10H10 VL9 (SEQ ID NO: 72)
[0692] Note: The single underlined part is CDR, the single underlined and bold part is the CDR amino acid substitution site, the double underlined and bold part is the FR amino acid substitution site, and the rest is the FR region, the same below.
[0693] Table 13. CDRs of hu10H10 humanized antibody
[0694] Table 14. 10H10 modified humanized antibodies
[0695] Table 15. CDR sequences of humanized antibody hu10H10-77
[0696] Note: CDRs are determined according to the Kabat numbering convention.
[0697] The heavy chain sequence and light chain sequence of the 10H10 humanized antibody are as follows:
[0698] hu10H10-1 / hu10H10-7 / hu10H10-13 / hu10H10-19 heavy chain:
[0699] hu10H10-2 / hu10H10-8 / hu10H10-14 / hu10H10-20 / hu10H10-57 / hu10H10-58 heavy chain:
[0700] hu10H10-3 / hu10H10-9 / hu10H10-15 / hu10H10-21 heavy chain:
[0701] hu10H10-4 / hu10H10-10 / hu10H10-16 / hu10H10-22 heavy chain:
[0702] hu10H10-5 / hu10H10-11 / hu10H10-17 / hu10H10-23 heavy chain:
[0703] hu10H10-6 / hu10H10-12 / hu10H10-18 / hu10H10-24 heavy chain:
[0704] hu10H10-25 / hu10H10-33 / hu10H10-41 / hu10H10-49 heavy chain:
[0705] hu10H10-26 / hu10H10-34 / hu10H10-42 / hu10H10-50 heavy chain:
[0706] hu10H10-27 / hu10H10-35 / hu10H10-43 / hu10H10-51 heavy chain:
[0707] hu10H10-28 / hu10H10-36 / hu10H10-44 / hu10H10-52 heavy chain:
[0708] hu10H10-29 / hu10H10-37 / hu10H10-45 / / hu10H10-53 / hu10H10-77 heavy chain:
[0709] hu10H10-30 / hu10H10-38 / hu10H10-46 / hu10H10-54 heavy chain:
[0710] hu10H10-31 / hu10H10-39 / hu10H10-47 / hu10H10-55 heavy chain:
[0711] hu10H10-32 / hu10H10-40 / hu10H10-48 / hu10H10-56 heavy chain:
[0712] hu10H10-1 / hu10H10-2 / hu10H10-3 / hu10H10-4 / hu10H10-5 / hu10H10-6 / hu10H10-25 / hu10H10-26 / hu10H10-27 / hu10H10-28 / hu10H10-29 / hu10H10-30 / hu10H10-31 / hu10H10-32 Light Chain:
[0713] hu10H10-7 / hu10H10-8 / hu10H10-9 / hu10H10-10 / hu10H10-11 / hu10H10-12 light chain:
[0714] hu10H10-13 / hu10H10-14 / hu10H10-15 / hu10H10-16 / hu10H10-17 / hu10H10-18 / hu10H10-33 / hu10H10-34 / hu10H10-35 / hu10H10-36 / hu10H10-37 / hu10H10-38 / hu10H10-39 / hu10H10-40 Light Chain:
[0715] hu10H10-19 / hu10H10-20 / hu10H10-21 / hu10H10-22 / hu10H10-23 / hu10H10-24 Light Chain:
[0716] hu10H10-41 / hu10H10-42 / hu10H10-43 / hu10H10-44 / hu10H10-45 / hu10H10-46 / hu10H10-47 / hu10H10-48 / hu10H10-57 Light Chain:
[0717] hu10H10-49 / hu10H10-50 / hu10H10-51 / hu10H10-52 / hu10H10-53 / hu10H10-54 / hu10H10-55 / hu10H10-56 / hu10H10-58 Light Chain:
[0718] hu10H10-77 light chain:
[0719] Example 10: Preparation of ADC
[0720] Determination of DAR value of ADC
[0721] The DAR value calculation method of the ADC disclosed herein adopts RP-HPLC (reverse phase high performance liquid chromatography).
[0722] The drug portion of the conjugate disclosed herein can be any suitable drug. Particularly suitable drugs are described, for example, in WO2020063676A1 (incorporated herein by reference in its entirety). Compound 9A of the present disclosure (i.e., compound 9-A of Example 9 of WO2020063676A1) has the following structure:
[0723] The present disclosure uses the following method to prepare an antibody-drug conjugate as shown in the ADC general formula (TF-9A) by adjusting reaction parameters.
[0724] Example 10-1 ADC-1
[0725] To a solution of antibody hu67Y116 in PBS buffer (pH = 6.5, 0.05 M) (10.0 mg / mL, 7.4 mL, 511 nmol) at 37°C, a prepared solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) in water (10 mM, 131.8 μL, 1.318 μmol) was added. The mixture was placed on a thermostatic shaker and incubated at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath.
[0726] Compound 9A (5.49 mg, 5.11 μmol) was dissolved in 370 mL of DMSO and added dropwise to the reaction solution. The mixture was placed on a thermostatted oscillator and incubated at 25°C for 3 hours, after which the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 His buffered aqueous solution) to obtain the exemplary product ADC-1 (hu67Y116-9A) of the conjugate TF-9A in His buffer (3.8 mg / mL, 17.6 mL), which was stored at 4°C. RP-HPLC calculated average DAR = 4.14.
[0727] Example 10-2 ADC-2
[0728] To a solution of antibody hu67Y116 in PBS buffer (pH = 6.5, 0.05 M) (10.0 mg / mL, 7.4 mL, 511 nmol) at 37°C, a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 178.9 μL, 1.789 μmol) was added. The mixture was shaken in a water bath at 37°C for 3 hours to stop the reaction. The reaction solution was cooled to 25°C in a water bath.
[0729] Compound 9A (6.586 mg, 6.132 μmol) was dissolved in 370 μL of DMSO and added to the above reaction solution. The mixture was placed in a water bath shaker and shaken at 25°C for 3 hours, after which the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 His buffer solution) to obtain an exemplary product of the conjugate TF-9A, ADC-2 (hu67Y116-9A), in PBS buffer (3.52 mg / mL, 17.9 mL). The product was stored at 4°C. RP-HPLC calculated average DAR = 5.91.
[0730] Example 10-3 ADC-3
[0731] To a solution of antibody hu67Y116 in PBS buffer (pH = 6.5, 0.05 M) (10.0 mg / mL, 1 mL, 69 nmol) at 37°C, add a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 48.3 μL, 483 nmol). Place the solution in a water bath shaker and incubate at 37°C for 3 hours to stop the reaction. Cool the reaction solution to 25°C in a water bath.
[0732] Compound 9A (1.1 mg, 1.035 μmol) was dissolved in 50 μL of DMSO and added to the above reaction solution. The mixture was shaken in a water bath at 25°C for 3 hours, and the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 His buffer solution) to obtain an exemplary product of the conjugate TF-9A, ADC-3 (hu67Y116-9A), in PBS buffer (0.8 mg / mL, 11.5 mL). The product was stored at 4°C. RP-HPLC calculated average DAR = 7.23.
[0733] Example 10-4 ADC-4
[0734] To a solution of antibody hu10H10-77 in PBS buffer (pH = 6.5, 0.05 M) (10.0 mg / mL, 8 mL, 549 nmol) at 37°C, add a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 145.5 μL, 1.455 μmol). Place the solution in a shaker water bath and incubate at 37°C for 3 hours to stop the reaction. Cool the reaction solution to 25°C in a water bath.
[0735] Compound 9A (5.9 mg, 5.49 μmol) was dissolved in 400 μL of DMSO and added to the above reaction solution. The mixture was shaken in a water bath at 25°C for 3 hours, and the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 His buffer solution) to obtain an exemplary product of the conjugate TF-9A, ADC-4 (hu10H10-77-9A), in PBS buffer (3.85 mg / mL, 19 mL). The product was stored at 4°C. RP-HPLC calculated average DAR = 4.2.
[0736] Example 10-5 ADC-5
[0737] To a solution of antibody hu10H10-77 in PBS buffer (pH = 6.5, 0.05 M) (10.0 mg / mL, 8 mL, 549 nmol) at 37°C, add a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 175.7 μL, 1.757 μmol). Place the solution in a shaker water bath and incubate at 37°C for 3 hours to stop the reaction. Cool the reaction solution to 25°C in a water bath.
[0738] Compound 9A (7.08 mg, 6.59 μmol) was dissolved in 400 μL of DMSO and added to the above reaction solution. The mixture was shaken in a water bath at 25°C for 3 hours, and the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 His buffer solution) to obtain an exemplary product of the conjugate TF-9A, ADC-5 (hu10H10-77-9A), in PBS buffer (3.57 mg / mL, 19.5 mL). The product was stored at 4°C. RP-HPLC calculated average DAR = 5.87.
[0739] Example 10-6 ADC-6
[0740] To a solution of antibody hu310-2 in PBS buffer (pH = 6.5, 0.05 M) (10.0 mg / mL, 8 mL, 553 nmol) at 37°C, add a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 124.4 μL, 1.244 μmol). Place the solution in a shaker water bath and incubate at 37°C for 3 hours to stop the reaction. Cool the reaction solution to 25°C in a water bath.
[0741] Compound 9A (5.94 mg, 5.53 μmol) was dissolved in 400 μL of DMSO and added to the above reaction solution. The mixture was shaken in a water bath at 25°C for 3 hours, and the reaction was stopped. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: pH 5.0 His buffer solution) to obtain an exemplary product of the conjugate TF-9A, ADC-6 (hu310-2-9A), in PBS buffer (3.77 mg / mL, 19.2 mL). The product was stored at 4°C. RP-HPLC calculated average DAR = 4.05.
[0742] Example 10-7 ADC-7
[0743] To a hIgG1 antibody solution in PBS buffer (pH 6.5, 0.05 M PBS buffer; 10.0 mg / mL, 1 mL, 67.6 nmol) at 37°C, add a prepared aqueous solution of tris(2-carboxyethyl)phosphine hydrochloride (TCEP.HCl) (10 mM, 16.6 uL, 166 nmol). Place in a water bath shaker and shake at 37°C for 3 hours to stop the reaction. Cool the reaction solution to 25°C in a water bath.
[0744] Compound 9A (0.73 mg, 676 nmol) was dissolved in 60 μL of dimethyl sulfoxide and added dropwise to the above reaction solution. The mixture was placed in a water bath shaker and shaken at 25°C for 3 hours to stop the reaction. The reaction solution was desalted and purified using a Sephadex G25 gel column (elution phase: 0.05 M PBS buffer solution at pH 6.5, containing 0.001 M EDTA) to obtain the title product ADC-7 in PBS buffer (0.91 mg / mL, 9.8 mL) and stored at 4°C.
[0745] RP-HPLC calculated average value: n=4.73.
[0746] Test example:
[0747] Test Example 1: Antibody Binding Experiment with Free Human and Monkey TF Protein
[0748] AffiniPure Goat Anti-Human IgG (Jackon, 109-005-008) protein was diluted to 2 μg / mL in PBS (Shanghai Yuanpei Biotechnology Co., Ltd., B320KJ) at pH 7.4 and added to a 96-well microtiter plate at a volume of 100 μL / well. The plate was incubated overnight at 4°C. After discarding the liquid, 300 μL of 5% skim milk (BD, 232100) diluted in PBS was added to each well for blocking and incubated at 37°C for 2 hours. After blocking, the blocking solution was discarded and the plate was washed three times with PBST buffer (pH 7.4 PBS containing 0.1% tween-20). Then, 50 μL of a 2 μg / mL diluted test antibody solution was added to each well and incubated at 37°C for 1 hour. After the incubation, the plate was washed three times with PBST, and 50 μL of biotinylated human or monkey TF-his protein (SEQ ID No. 5 / 8) (biotin labeling kit: DO JINDO, LK03-10) with a gradient dilution (10 μg / mL, 5-fold gradient dilution) was added to each well and incubated at 37°C for 1 hour. After the incubation, the plate was washed three times with PBST, and Streptavidin-Peroxidase Polymer (sigma, S2438-250UG) was added at a dilution of 1:8000 and incubated at 37°C for 1 hour. After washing the plate three times with PBST, 50 μL of TMB colorimetric substrate (KPL, 5120-0077) was added to each well and incubated at room temperature for 5 minutes. 50 μL of 1 M H2SO4 was added to each well to terminate the reaction. The absorbance at 450 nm was read using a microplate reader, and the binding curve of the antibody and antigen was fitted using GraphPad Prism to calculate the EC 50 value.
[0749] Table 16: Binding of antibodies to free TF
[0750] The antibodies disclosed herein have good binding activity to TF antigen.
[0751] Test Example 2: Antibody-cell binding experiment
[0752] MDA-MB-231 cells, NCI-H358 (abbreviated as H358 cells), and HCT116 cells were prepared into 1×10 6100 μL / well of a cell suspension of 100 cells / mL was added to a 96-well round-bottom plate. After centrifugation to remove the supernatant, 100 μL / well of the test antibody diluted with FACS buffer at different concentrations (60 μg / mL, 3-fold serial dilution) was added and incubated at 4°C in the dark for 1 hour. After washing three times with FACS buffer at 300g, the working concentration of APC Rat Anti-human IgG Fc (BioLegend, 410712) was added and incubated at 4°C in the dark for 40 minutes. After washing three times with FACS buffer at 300g, the geometric mean fluorescence intensity was measured using a Thermo Attune Nxt flow cytometer to calculate the EC 50 value.
[0753] Table 17. Binding of antibodies to cells
[0754] The antibodies disclosed herein have good binding activity to cells expressing TF antigen.
[0755] Test Example 3: Affinity Binding Experiment
[0756] The antibody sample was prepared at a 4 μg / mL solution in 1× HBS-EP buffer (pH 7.4) (Cytiva, BR-1006-69). The antibody was affinity-captured using a Protein A biosensor chip (Cytiva, 29127556). A specific concentration of the antigen, human TF-His protein (SEQ ID NO: 5) or monkey TF-His protein (SEQ ID NO: 8), was then passed over the chip surface. Binding and dissociation curves were obtained using a Biacore T200 (Cytiva) instrument to monitor the reaction signal in real time. After each experimental cycle, the biosensor chip was washed and regenerated with 10 mM glycine-HCl (pH 1.5) (Cytiva, BR-1003-54). A 1:1 binding model was used for data fitting. The test results are shown in Table 18.
[0757] Table 18. Antibody Affinity
[0758] The disclosed antibodies have a higher affinity for TF antigen.
[0759] Test Example 4: Antibody Binding Experiment with Mouse and Rat TF Protein
[0760] Mouse TF-His protein (SEQ ID NO: 10) or rat TF-His protein (SEQ ID NO: 9) was diluted to 4 μg / mL in PBS buffer (pH 7.4) and added to a 96-well microtiter plate at a volume of 100 μL / well. Incubate at 4°C overnight. After discarding the supernatant, 300 μL of 5% skim milk (BD, 232100) diluted in PBS was added to each well for blocking and incubated at 37°C for 2 hours. After blocking, the blocking solution was discarded and the plate was washed three times with PBST buffer (pH 7.4 PBS containing 0.1% tween-20). Then, 100 μL of serially diluted antibody solution was added to each well and incubated at 37°C for 1 hour. After incubation, the plate was washed three times with PBST, and 100 μL of a 1:4000 dilution of Peroxidase AffiniPure Goat Anti-Human IgG (H+L) (Jackson, 109-035-003) was added to each well and incubated at 37°C for 1 hour. After washing the plate three times with PBST, 50 μL of TMB chromogenic substrate (KPL, 5120-0077) was added to each well and incubated at room temperature for 5 minutes. The reaction was terminated by adding 50 μL of 1 M H2SO4 to each well. The absorbance at 450 nm was read using a microplate reader, and the antibody-antigen binding curve was fitted using GraphPad Prism (Figures 1 and 2).
[0761] The results showed that hu10H10-77, hu310-2, and hu67Y116 did not bind to the mouse TF-His protein ( FIG. 1 ) or the rat TF-His protein ( FIG. 2 ).
[0762] Test Example 5: Factor-VII-Human Chromogenic-Activity Coagulation Pathway Experiment
[0763] In the TF-FVII-FX pathway, TF affects the generation of FX substrates, ultimately affecting coagulation. This test is used to examine the effects of different antibodies on the coagulation pathway.
[0764] A 96-well plate in the Factor-VII-Human Chromogenic-Activity kit (Abcam, ab 108830) was incubated at room temperature for approximately 10 minutes. Then, 100 μL / well of 0.5 μg / mL FVIIa (recombinant human coagulation factor VIIa for injection, i.e., NovoSeven) was added and incubated at 37°C for 2 hours. After incubation, the plate was washed five times with wash buffer (provided by the kit). 40 μL / well of the diluted antibody was added, followed by 40 μL / well of a mixture of MDA-MB-231 cells and FX (provided by the kit) and incubated at 37°C for half an hour. The reaction was initiated by adding 20 μL / well of substrate (provided by the kit). The absorbance at 405 nm was read using a microplate reader at 3-minute intervals for 30 minutes. The value of the well without antibody was defined as the maximum value (MAX), and the value of the well without FVIIa was defined as the minimum value (MIN). Data within the linear range were used to calculate the ratio of the coagulation pathway. The coagulation ratio values are shown in Table 19.
[0765] Table 19. Coagulation test
[0766] The results showed that the three antibodies disclosed herein did not affect the coagulation pathway, while the positive controls TF011 and H39 affected the coagulation pathway.
[0767] Test Example 6: DT3C endocytosis experiment
[0768] After DT3C protein enters the cell, the activated diphtheria toxin (DT) kills the cell, which indirectly reflects the internalization of the antibody. 50 and Imax to evaluate the in vitro endocytic activity of antibodies.
[0769] DT3C is a recombinantly expressed fusion protein composed of Fragment A (toxin portion only) of diphtheria toxin and Fragment 3C (IgG-binding portion) of group G Streptococcus. This protein has a high affinity for the Fc structure of antibodies and enters cells together with the antibody during endocytosis. Under the action of intracellular furin, the toxic DT is released. DT inhibits EF2-ADP ribosylation, blocks protein translation, and ultimately leads to cell death. DT3C that does not enter cells has no cytotoxic activity. The endocytic activity of the antibody is evaluated based on the cell killing effect.
[0770] MDA-MB-231 cell suspension was prepared using fresh cell culture medium containing 20% low IgG FBS (Gibco, 1921005PJ) at a cell density of 4×10 4cells / mL, added into the cell culture plate at 50 μL / well, i.e., 2000 cells per well, and cultured at 37°C with 5% carbon dioxide for 16 hours.
[0771] Prepare DT3C at a 4x concentration (120 μg / mL) in serum-free RPMI 1640 medium and sterilize by filtration through a 0.22 μm filter. Prepare the antibody at a 4x concentration (40 μg / mL) in serum-free RPMI 1640 medium. Mix 80 μL of DT3C (approximately 70 kD) and 80 μL of antibody (approximately 145 kD) in a 1:1 ratio. Incubate at room temperature for 30 minutes. Then, add 40 μL of the mixture to 120 μL of serum-free RPMI 1640 medium. Retain the well containing only 160 μL of serum-free RPMI 1640 medium. The final antibody concentration is 10 μg / mL. The well containing only medium serves as the zero point for calculating endocytosis rate. Add 50 μL of the diluted antibody to 50 μL of cells and incubate at 37°C, 5% CO2 for three days. 50 μL CellTiter-Glo™ (CTG) (Promega, G7573) was added to each well and incubated in the dark at room temperature for 10 minutes. Chemiluminescence was read on ENVISION. The results are shown in Table 20.
[0772] Table 20. Endocytic activity of antibodies
[0773] The results showed that the antibodies disclosed herein have endocytic activity.
[0774] Test Example 7: Prothrombin Time (PT) Test
[0775] The effect of anti-TF antibodies on the in vitro PT of human plasma was evaluated by measuring the PT values of human plasma spiked with anti-TF antibodies. Venous blood was drawn from an upper limb vein of a volunteer and poured into a 15 mL centrifuge tube. 3.8% trisodium citrate anticoagulant (Sinopharm Chemical Reagent Co., Ltd., 6132-04-3) (anticoagulant: whole blood = 1:9) was pre-added. The tube was centrifuged at 2500 rpm for 10 minutes at room temperature to collect plasma. The test antibody was prepared in PBS (Meilun Biotechnology, PWL050) at working concentrations of 16000 nM, 8000 nM, 4000 nM, 2000 nM, 1000 nM, and 500 nM (final concentrations: 1600 nM, 800 nM, 400 nM, 200 nM, 100 nM, and 50 nM). PT reagent (Shanghai Dacheng Medical Equipment Co., Ltd., OUHP29) was added to 4 mL of purified water and incubated at 37°C for 30 minutes. According to the CA600 coagulometer (Sysmex) operating manual, human plasma, PT reagent, test antibody, blank PBS, and Clean I (Shanghai Dacheng Medical Equipment Co., Ltd., GSA-500A) were placed in the designated positions of the instrument. The program was started to measure the PT value. The results were obtained using GraphPad Prism for curve fitting and analysis and calculation (Table 21). The effect of the antibody on the PT was primarily determined based on the reading of the maximum antibody concentration.
[0776] Table 21. PT test results
[0777] The results showed that none of the three antibodies disclosed herein affected coagulation, and their effects on PT were smaller than those of TF011 and H39. TF011 exhibited a significant inhibitory effect on coagulation in the PT experiment.
[0778] Test Example 8: Binding experiment between antibody and human-rat hybrid TF protein HuRatTF
[0779] To screen for antibodies targeting specific epitopes of human TF that do not affect human coagulation function after binding, the human-rat hybrid antigen HuRatTF protein (SEQ ID No. 11) described in Example 1 was constructed and used in antibody binding experiments. The HuRatTF protein has mutated several sites that affect coagulation to alanine (Ala) and contains partial human and rat sequences.
[0780] HuRatTF protein was diluted to 4 μg / mL in PBS buffer (pH 7.4) and added to a 96-well microtiter plate at a volume of 100 μL / well. The plates were incubated overnight at 4°C. The supernatant was discarded, and 300 μL of 5% skim milk (BD, 232100) diluted in PBS was added to each well for blocking. The plates were incubated at 37°C for 2 hours. After blocking, the blocking buffer was discarded, and the plates were washed three times with PBST buffer (pH 7.4 PBS containing 0.1% tween-20). 100 μL of a serially diluted antibody solution (starting at 20 μg / mL, with 5-fold dilutions) was added to each well and incubated at 37°C for 1 hour. After incubation, the plates were washed three times with PBST, and 100 μL of a 1:4000 dilution of Peroxidase AffiniPure Goat Anti-Human IgG (H+L) (Jackson, 109-035-003) was added to each well and incubated at 37°C for 1 hour. After washing the plate three times with PBST, 50 μL of TMB chromogenic substrate (KPL, 5120-0077) was added to each well and incubated at room temperature for 5 minutes. The reaction was terminated by adding 50 μL of 1 M H2SO4 to each well. The absorbance at 450 nm was read using a microplate reader. The binding curve of the antibody and antigen was fitted using GraphPad Prism. The data are shown in Table 22.
[0781] Table 22. Binding assay results of antibodies and HuRatTF protein
[0782] The results showed that the antibody TF011, which has an effect on coagulation function, does not bind to the HuRatTF protein, while the disclosed antibody, which has no effect on coagulation function, can bind to the HuRatTF protein.
[0783] Test Example 9: IL-8 cytokine test experiment
[0784] MDA-MB-231 cells were cultured in serum-free medium to a volume of 3 × 10 5 100 μL / well of a cell suspension of 100 cells / mL was added to a 96-well plate and incubated at 37°C for 2 hours. The supernatant was discarded and 100 μL / well of a gradient dilution (10 μg / mL starting, 6-fold gradient dilution) antibody prepared in serum-free medium was added and incubated at 37°C for 0.5 hours. The supernatant was discarded and 120 μL / well of FVIIa (recombinant human coagulation factor VIIa for injection, NovoSeven) prepared in serum-free medium was added and incubated at 37°C for 5 hours. After the incubation was completed, centrifuged at 300g for 5 minutes, and 100 μL of the supernatant was transferred to a 96-well plate in the IL-8 kit (Xinbosheng Bio, EHC008), and the IL-8 test was performed according to the instructions. The absorbance at 450 nm was read using an enzyme reader, and the binding curve of the antibody and antigen was fitted using GraphPad Prism. The EC was calculated.50 The results are shown in Table 23.
[0785] Table 23. IL8 Experiment
[0786] The results showed that the antibodies disclosed herein had a strong inhibitory effect on IL8.
[0787] Test Example 10: ADC Molecular Cell Activity Experiment
[0788] The purpose of this experiment is to detect the cell killing effect of ADC samples. 50 and Imax were used to evaluate the in vitro activity of ADC.
[0789] HPAFⅡ cells (human pancreatic cancer cells), MDA-MB-231 cells (human breast cancer cells), H358 cells (human non-small cell lung cancer cells) and CHO-K1 cells (hamster ovary cells) were trypsinized, neutralized with fresh culture medium, centrifuged at 1000 rpm and resuspended in culture medium. After counting, the cell suspension densities were adjusted to 3700 cells / mL for HPAFⅡ cells, 7400 cells / mL for MDA-MB-231 cells, 7400 cells / mL for H358 cells and 3700 cells / mL for CHO-K1 cells, respectively. 135 μL of the cell suspension was added to a 96-well cell culture plate, i.e., 500 HPAFⅡ cells per well, 1000 cells per well for MDA-MB-231 cells, 1000 cells per well for H358 cells and 500 cells per well for CHO-K1 cells. No cells were plated in column 11, but only 135 μL of culture medium was added. The plates were incubated at 37°C in 5% carbon dioxide for 16 hours.
[0790] The ADC sample was diluted to 3.333 μM (10× concentration) with PBS. This was the initial concentration, and a five-fold serial dilution series was performed with PBS for a total of nine concentrations. 15 μL of the 10× serial dilution solution was added to each well, with culture medium in wells 10 and 11. Each concentration point was replicated and incubated at 37°C with 5% CO2 for 6 days.
[0791] After the incubation is complete, add 50 μL of CTG to each well and incubate in the dark at room temperature for 10 minutes. A white film is attached to the bottom of the cell culture plate and the plate is placed on an ENVISION monitor for chemiluminescence reading. The results of in vitro cell cytotoxicity are shown in Table 24.
[0792] Table 24. In vitro cell killing activity of ADCs
[0793] The results showed that the above ADC had a strong killing effect on the cell lines HPAFⅡ, MDA-MB-231, and H358.
[0794] Test Example 11: In vivo efficacy experiment of HPAFII in CDX model
[0795] This test case evaluates and compares the efficacy of various ADC drugs on subcutaneous transplanted tumors in NUNU mice.
[0796] Each NUNU mouse (4-6 weeks old, ♀, SPF grade, Beijing Weitonglihua Laboratory Animal Co., Ltd.) was subcutaneously inoculated with 4×10 6 / 200μL (containing 50% matrigel) HPAF-Ⅱ cells (human pancreatic cancer), wait until the tumor grows to 250-300mm 3 After approximately 24 hours, animals were divided into groups based on tumor volume (D0). Mice were administered intraperitoneally (IP) once weekly for a total of three doses. The weekly dose volume was 10 mL / kg; the specific dosage and dosing schedule are shown in Table 25. Tumor volume was measured twice weekly, and mice were weighed and the data were recorded.
[0797] The experimental indicators are to examine the effect of drugs on tumor growth, specifically T / C% or tumor inhibition rate TGI%. Tumor diameter is measured with a vernier caliper twice a week, and tumor volume (V) is calculated as: V = 1 / 2 × a × b 2 , where a and b represent length and width, respectively. T / C% = (T-T0) / (C-C0) × 100, where T and C represent the tumor volumes at the end of the experiment; T0 and C0 represent the tumor volumes at the start of the experiment. T represents the tumor volume in the ADC-treated group, and C represents the tumor volume in the control group. Tumor growth inhibition rate (TGI%) = 100-T / C%. When tumor regression occurs, tumor growth inhibition rate (TGI%) = 100-(T-T0) / T0 × 100. If the tumor is smaller than the starting volume, that is, T < T0 or C < C0, it is defined as partial tumor regression (PR); if the tumor completely disappears, it is defined as complete tumor regression (CR). Unless otherwise specified, a two-way ANOVA test was used to compare the tumor volumes between the two groups, and a P < 0.05 was defined as a statistically significant difference. Please see Table 25 for the results.
[0798] Table 25. Efficacy of ADC on HPAF-Ⅱ subcutaneous transplanted tumors in nude mice
[0799] P values refer to the comparison with the blank control group; IP: intraperitoneal injection; partial regression: the tumor volume on D25 was smaller than that on D0.
[0800] After three doses, both the ADC-4 (2 mg / kg) and ADC-1 (2 mg / kg) groups showed significant efficacy against HPAF-II subcutaneous xenografts in nude mice, with significant differences compared to the blank control group. The drugs showed a clear dose-dependent effect. Tumor-bearing mice tolerated all of the drugs well.
[0801] Test Example 12: In vivo efficacy experiment of H358 in CDX model
[0802] This test case evaluates and compares the efficacy of various ADC drugs on subcutaneous transplanted tumors in nude mice.
[0803] Each nude mouse (4-6 weeks old, ♀, SPF grade, Shanghai Slake Laboratory Animal Co., Ltd.) was subcutaneously inoculated with 5×10 6 / 200μL (containing 50% matrigel) H358 cells (human non-small cell lung cancer), wait until the tumor grows to 300mm 3 After approximately 24 hours, animals were divided into groups based on tumor volume (D0). Mice were administered intraperitoneally (IP) once weekly for a total of three doses. The weekly dose volume was 10 mL / kg; the specific dosage and dosing schedule are shown in Table 26. Tumor volume was measured twice weekly, and mice were weighed and the data were recorded.
[0804] The experimental indicators are to examine the effect of drugs on tumor growth, specifically T / C% or tumor inhibition rate TGI%. Tumor diameter is measured with a vernier caliper twice a week, and tumor volume (V) is calculated as: V = 1 / 2 × a × b 2 , where a and b represent length and width, respectively. T / C% = (T-T0) / (C-C0) × 100, where T and C represent the tumor volumes at the end of the experiment; T0 and C0 represent the tumor volumes at the start of the experiment. T represents the tumor volume in the ADC-treated group, and C represents the tumor volume in the control group. Tumor growth inhibition rate (TGI%) = 100-T / C%. When tumor regression occurs, tumor growth inhibition rate (TGI%) = 100-(T-T0) / T0 × 100. If the tumor is smaller than the starting volume, that is, T < T0 or C < C0, it is defined as partial tumor regression (PR); if the tumor completely disappears, it is defined as complete tumor regression (CR). Unless otherwise specified, a two-way ANOVA test was used to compare the tumor volumes between the two groups, and a P < 0.05 was defined as a statistically significant difference. Please see Table 26 for the results.
[0805] Table 26. Efficacy of ADC on subcutaneous transplanted tumors in H358 nude mice
[0806] P values refer to the comparison with the negative antibody group; IP: intraperitoneal injection; partial regression: the tumor volume on D32 was smaller than that on D0.
[0807] After three doses of ADC-1 (3 mg / kg, 1 mg / kg), ADC-4 (3 mg / kg, 1 mg / kg), and ADC-6 (3 mg / kg, 1 mg / kg) all showed significant tumor suppression, leading to partial tumor regression. The drugs were dose-dependent and well-tolerated by tumor-bearing mice.
[0808] Test Example 13: In vivo efficacy study of MDA-MB-231 in the CDX model
[0809] This test case evaluates and compares the efficacy of various ADC drugs on subcutaneous xenograft tumors in NOD scid mice.
[0810] Each NOD scid mouse (4-6 weeks old, ♀, SPF grade, Shanghai Slake Laboratory Animal Co., Ltd.) was subcutaneously inoculated with 3×10 6 / 100 μL (containing 50% matrigel) MDA-MB-231 cells (human breast cancer), wait until the tumor grows to 250-300 mm 3 After about 14 days, the animals were divided into groups based on tumor volume (D0). Mice were intraperitoneally injected (IP) with the drug once a week for a total of three doses. The weekly dose volume was 10 mL / kg. Tumor volume was measured twice a week, and the mice were weighed and the data were recorded.
[0811] The experimental indicators are to examine the effect of drugs on tumor growth, specifically T / C% or tumor inhibition rate TGI%. Tumor diameter is measured with a vernier caliper twice a week, and tumor volume (V) is calculated as: V = 1 / 2 × a × b 2 , where a and b represent length and width, respectively. T / C% = (T-T0) / (C-C0) × 100, where T and C represent the tumor volumes at the end of the experiment; T0 and C0 represent the tumor volumes at the start of the experiment. T represents the tumor volume in the ADC-treated group, and C represents the tumor volume in the control group. Tumor growth inhibition rate (TGI%) = 100-T / C%. When tumor regression occurs, TGI% = 100-(T-T0) / T0 × 100. If the tumor is smaller than the starting volume, that is, T < T0 or C < C0, it is defined as partial tumor regression (PR); if the tumor disappears completely, it is defined as complete tumor regression (CR). Unless otherwise specified, a two-way ANOVA test was used to compare tumor volumes between the two groups, and a statistically significant difference of P < 0.05 was defined. All of the above drugs were well tolerated by tumor-bearing mice, with no significant symptoms such as weight loss. PBS was used as a blank control. Please see Table 27 for the results.
[0812] Table 27. Efficacy of ADC on subcutaneous transplanted tumors in MDA-MB-231 mice
[0813] P values refer to the comparison with the blank control group; IP: intraperitoneal injection; partial regression: the tumor volume on D21 was smaller than that on D0.
[0814] After three doses, ADC-1 (3 mg / kg, 1 mg / kg), ADC-2 (1 mg / kg), ADC-3 (1 mg / kg), ADC-6 (3 mg / kg, 1 mg / kg), and hIgG-9A (3 mg / kg) all demonstrated significant therapeutic effects against subcutaneous MDA-MB-231 tumors in mice, with significant differences compared to the blank control group. The drugs exhibited a clear dose-dependent effect. All of the drugs were well tolerated by the tumor-bearing mice.
[0815] Test Example 14: PK and toxicity observation experiment in cynomolgus monkeys
[0816] This test case evaluated the PK of ADC-1 and ADC-2 in cynomolgus monkeys and simultaneously observed toxicity.
[0817] Each cynomolgus macaque (Suzhou Xishan Zhongke Laboratory Animal Co., Ltd.; SCXK(Su)2018-0001) was administered 12 mg / kg via intravenous infusion. Blood was collected for plasma drug concentration determination and other toxicological observations at 0.083 h (5 min ± 1 min), 1 h (± 5 min), 6 h (± 15 min), 12 h (± 15 min), 24 h (± 30 min), 48 h (± 30 min), 96 h (± 30 min), 168 h (± 30 min), 240 h (± 60 min), 336 h (± 60 min), and 504 h (± 60 min) after administration.
[0818] The PK assay used the LBA method (Delfia) to quantitatively detect the concentrations of total antibodies and intact ADC of ADC-1 in cynomolgus monkey serum.
[0819] Table 28. Pharmacokinetics of ADC-1 in cynomolgus monkeys: Total antibody and intact ADC plasma concentrations
[0820] Table 29. Pharmacokinetics of ADC-2 in cynomolgus monkeys: Total antibody and intact ADC plasma concentrations
[0821] The half-life and AUC of the total antibodies and intact ADCs of ADC-1 and ADC-2 molecules in crab-eating monkeys are basically the same, and ADC-1 and ADC-2 molecules have good stability in crab-eating monkeys; due to the presence of immunogenicity, the half-life and AUC of the second administration are lower than those of the first administration.
[0822] For ADC-1 pharmacokinetic testing, blood was collected from all animals before the first dose, on the second day, and on the eighth day for coagulation testing. Animals were fed overnight before blood collection. Prothrombin time (PT) and activated thrombin time (APTT) were measured using a Sysmex CS-2000i fully automated coagulation analyzer or a Sysmex CA-1500 automated coagulation analyzer. PT and APTT results are shown in Figures 3 and 4. These results show no significant prolongation of clotting time or increased risk of bleeding compared to pre-dose administration.
[0823] Test Example 15: TGA Experiment
[0824] This test example tests whether the antibody hu67Y116 affects the coagulation activity of TF.
[0825] Human plasma contains coagulation factors other than TF, including FVII, FX, FV, FII, and FI. If the antibody does not affect the coagulation activity of TF, it will not affect the clotting time and peak value of human plasma. Human plasma was prepared according to the Technothrombin TGA Kit instructions. Then, a 20X concentration of antibody was prepared. Antibody and plasma were mixed at a ratio of 1:19, and 40 μL / well was added to a black 96-well plate. Then, 10 μL / well of RCH (TGA reagent C high, included in the kit) was added, and finally, 50 μL / well of substrate was added to initiate the reaction. Fluorescence was measured using a microplate reader (excitation at ~360 nm / emission at ~460 nm). The results are shown in Table 30. TF011 significantly inhibited coagulation compared to the negative control antibody, while hu67Y116 had little effect on coagulation.
[0826] Table 30. TGA experimental results
Claims
1. An anti-TF antibody, wherein the anti-TF antibody comprises a heavy chain variable region and a light chain variable region, wherein: a. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 40, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 64 or 41, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 65 or 42, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 66 or 43, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 67 or 44, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 68, 83 or 45; b. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 46, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 47, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 48, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 49, 111, 112 or 113, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 50, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 51; c. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 73 or 144, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 74, 142, 145 or 146, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 75 or 143, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 76, 151, 147 or 150, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 77 or 148, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 78 or 149; Preferably, a. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 40, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 64, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 65, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 66, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 67, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 68 or 83; or the heavy chain variable region's HCDR1 comprises the amino acid sequence of SEQ ID NO:40, HCDR2 comprises the amino acid sequence of SEQ ID NO:41, and HCDR3 comprises the amino acid sequence of SEQ ID NO:42, and the light chain variable region's LCDR1 comprises the amino acid sequence of SEQ ID NO:43, LCDR2 comprises the amino acid sequence of SEQ ID NO:44, and LCDR3 comprises the amino acid sequence of SEQ ID NO:45; b. HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 46, HCDR2 comprises the amino acid sequence of SEQ ID NO: 47, and HCDR3 comprises the amino acid sequence of SEQ ID NO: 48, and LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 49, LCDR2 comprises the amino acid sequence of SEQ ID NO: 50, and LCDR3 comprises the amino acid sequence of SEQ ID NO: 51; c. the HCDR1 of the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 73, the HCDR2 comprises the amino acid sequence of SEQ ID NO: 74, and the HCDR3 comprises the amino acid sequence of SEQ ID NO: 75, and the LCDR1 of the light chain variable region comprises the amino acid sequence of SEQ ID NO: 76 or 151, the LCDR2 comprises the amino acid sequence of SEQ ID NO: 77 or 148, and the LCDR3 comprises the amino acid sequence of SEQ ID NO: 78 Amino acid sequence.
2. The anti-TF antibody according to claim 1, which is a murine antibody, a chimeric antibody or a humanized antibody; preferably, it is a chimeric antibody or a humanized antibody; more preferably, it is a humanized antibody.
3. The anti-TF antibody according to claim 1 or 2, comprising a heavy chain variable region and a light chain variable region, wherein: a. the heavy chain variable region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 62, 58, 130, 131 or 132, and the light chain variable region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 63, 81, 59, 133, 134 or 135; or the heavy chain variable region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 36, and the light chain variable region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 37; b. the heavy chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO:52 or 114, and the light chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO:53, 115, 116, 117, 118, 119, 120 or 121; or the heavy chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO:38, and the light chain variable region comprises an amino acid sequence that has at least 80% sequence identity to SEQ ID NO:39; c. the heavy chain variable region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:71, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 or 96, and the light chain variable region comprises an amino acid sequence having at least 80% sequence identity to SEQ ID NO:72, 97, 102, 98, 99, 100 or 101; Preferably, a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 62, 58, 130, 131 or 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 63, 81, 59, 133, 134 or 135; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 37; b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 52 or 114, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 53, 115, 116, 117, 118, 119, 120 or 121; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 38, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39; c. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 71, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95 or 96, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72, 97, 102, 98, 99, 100 or 101; More preferably, a. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 62, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 63 or 81; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 36, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 37; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 133; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 134; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 59; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 130, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 131, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; or The heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 58, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 132, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 135; b. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 52, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 53; or the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 38, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 39; c. the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 71, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 72, 97 or 102.
4. The anti-TF antibody according to any one of claims 1 to 3, which is an antibody fragment; preferably, it is selected from Fab, Fab', F(ab')2, Fd, Fv, scFv, dsFv and dAb.
5. The anti-TF antibody according to any one of claims 1 to 4, comprising a heavy chain constant region and a light chain constant region; preferably, the heavy chain constant region is a human IgG1, IgG2, IgG3 and IgG4 heavy chain constant region, and the light chain constant region is a human κ or λ chain constant region; more preferably, the heavy chain constant region comprises the amino acid sequence of SEQ ID NO: 54, and the light chain constant region comprises the amino acid sequence of SEQ ID NO:
55.
6. The anti-TF antibody according to any one of claims 1 to 5, which is selected from the antibody comprising a heavy chain and a light chain according to any one of the following: a. a heavy chain having at least 80% sequence identity with SEQ ID NO: 69, 60, 136, 137 or 138, and / or a light chain having at least 80% sequence identity with SEQ ID NO: 70, 82, 61, 139, 140 or 141; or a heavy chain having at least 80% sequence identity to SEQ ID NO: 107, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 108; b. a heavy chain having at least 80% sequence identity to SEQ ID NO: 56 or 122, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 57, 123, 124, 125, 126, 127, 128 or 129; or a heavy chain having at least 80% sequence identity to SEQ ID NO: 109, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 110; c. a heavy chain having at least 80% sequence identity to SEQ ID NO: 79, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163 or 164, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 80, 165, 170, 166, 167, 168 or 169; Preferably, a. a heavy chain having at least 80% sequence identity with SEQ ID NO: 69, and / or a light chain having at least 80% sequence identity with SEQ ID NO: 70 or 82; or A heavy chain having at least 80% sequence identity to SEQ ID NO:60, and / or a light chain having at least 80% sequence identity to SEQ ID NO:61; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 107, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 108; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a heavy chain having at least 80% sequence identity to SEQ ID NO: 139 A light chain having at least 80% sequence identity; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 139; or A heavy chain having at least 80% sequence identity to SEQ ID NO:60, and / or a light chain having at least 80% sequence identity to SEQ ID NO:139; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 139; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or A heavy chain having at least 80% sequence identity to SEQ ID NO:60, and / or a light chain having at least 80% sequence identity to SEQ ID NO:140; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 140; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 61; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 136, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141; or A heavy chain having at least 80% sequence identity to SEQ ID NO: 137, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141; or A heavy chain having at least 80% sequence identity to SEQ ID NO:60, and / or a light chain having at least 80% sequence identity to SEQ ID NO:141; or a heavy chain having at least 80% sequence identity to SEQ ID NO: 138, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 141; b. a heavy chain having at least 80% sequence identity to SEQ ID NO: 56, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 57; or a heavy chain having at least 80% sequence identity to SEQ ID NO: 109, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 110; c. A heavy chain having at least 80% sequence identity to SEQ ID NO: 79, and / or a light chain having at least 80% sequence identity to SEQ ID NO: 80, 165 or 170; More preferably, a. the heavy chain comprises the amino acid sequence of SEQ ID NO: 69, and the light chain comprises the amino acid sequence of SEQ ID NO: 70; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 69, and the light chain comprises the amino acid sequence of SEQ ID NO: 82; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 107, and the light chain comprises the amino acid sequence of SEQ ID NO: 108; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 139; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 140; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 61; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 136, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 137, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 60, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 138, and the light chain comprises the amino acid sequence of SEQ ID NO: 141; b. the heavy chain comprises the amino acid sequence of SEQ ID NO: 56, and the light chain comprises the amino acid sequence of SEQ ID NO: 57; or The heavy chain comprises the amino acid sequence of SEQ ID NO: 109, and the light chain comprises the amino acid sequence of SEQ ID NO: 110; c. the heavy chain comprises the amino acid sequence of SEQ ID NO: 79, and the light chain comprises the amino acid sequence of SEQ ID NO: 80 or The heavy chain comprises the amino acid sequence of SEQ ID NO: 79, and the light chain comprises the amino acid sequence of SEQ ID NO: 165; or The heavy chain comprises the amino acid sequence of SEQ ID NO:79, and the light chain comprises the amino acid sequence of SEQ ID NO:
170.
7. A nucleic acid molecule encoding the anti-TF antibody according to any one of claims 1 to 6. A host cell comprising the nucleic acid molecule according to claim 7 .
9. An immunoconjugate comprising: the anti-TF antibody according to any one of claims 1 to 6 and an effector molecule, wherein: The effector molecule is coupled to the anti-TF antibody; preferably, the effector molecule is selected from anti-tumor agents, immunomodulators, biological response modifiers, lectins, cytotoxic drugs, chromophores, fluorophores, chemiluminescent compounds, enzymes, metal ions, and any combination thereof.
10. An antibody-drug conjugate represented by the general formula (Pc-LYD) or a pharmaceutically acceptable salt thereof: in: Y is -O-(CR a R b ) m -CR 1 R 2 -C(O)-; Among them, R a and R b are the same or different and are each independently selected from hydrogen atoms, deuterium atoms, halogens and C 1-6 alkyl; R 1 C 3-6 Cycloalkyl-C 1-6 Alkyl or C 3-6 Cycloalkyl; R 2 Selected from hydrogen atoms, halogenated C 1-6 Alkyl and C 3-6 Cycloalkyl; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; m is an integer from 0 to 4; L is the joint unit; n is 1 to 10; preferably, n is 1 to 8; more preferably, n is 2 to 8; Pc is the anti-TF antibody according to any one of claims 1 to 6.
11. The antibody-drug conjugate represented by the general formula (Pc-LYD) according to claim 10 or a pharmaceutically acceptable salt thereof, wherein the linker unit -L- is -L 1 -L 2 -L 3 -L 4 -, in, L 1 Selected from -(succinimidyl-3-yl-N)-WC(O)-, -CH2-C(O)-NR 3 -WC(O)- and -C(O)-WC(O)-, wherein W is selected from C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 Cycloalkyl, wherein the C 1-6 Alkylene or C 1-6 Alkylene-C 3-6 The cycloalkyl groups are each independently optionally selected from halogen, hydroxy, cyano, amino, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl, C 1-6 Alkoxy and C 3-6 The cycloalkyl group is substituted by one or more substituents; L 2 Selected from -NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20; L 3 A peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 4 Selected from -NR 5 (CR 6 R 7 ) t -、-C(O)NR 5 -、-C(O)NR 5 (CH2) t - and chemical bonds, wherein t is an integer from 1 to 6; R 3 , R 4 and R 5 are the same or different and are each independently selected from a hydrogen atom, a C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Hydroxyalkyl; R 6 and R 7 are the same or different and are each independently selected from hydrogen atoms, halogens, C 1-6 Alkyl, halogenated C 1-6 Alkyl, deuterated C 1-6 Alkyl and C 1-6 Hydroxyalkyl; Preferably, the linker unit-L 1 -L 2 -L 3 -L 4 -as follows: L 1 for where s 1 is an integer from 2 to 8; L 2 is a chemical bond; L 3 is a tetrapeptide residue; preferably, L 3 is a tetrapeptide residue as shown in GGFG (SEQ ID NO: 105); L 4 For-NR 5 (CR 6 R 7 )t-, where R 5 , R 6 or R 7 are the same or different and are each independently a hydrogen atom or a C 1-6 Alkyl, t is 1 or 2; wherein the -L- 1 The end is connected to Pc, L 4 Connect the Y end.
12. The antibody-drug conjugate of the general formula (Pc-LYD) according to claim 10 or 11, or a pharmaceutically acceptable salt thereof, which is the general formula (Pc-L a -YD) shown in the antibody-drug conjugate or a pharmaceutically acceptable salt thereof: in, Pc is an anti-TF antibody according to any one of claims 1 to 6; m is an integer from 0 to 4; n is 1 to 10; R 1 C 3-6 Cycloalkyl-C 1-6 Alkyl or C 3-6 Cycloalkyl; R 2 Selected from hydrogen atoms, halogenated C 1-6 Alkyl and C 3-6 Cycloalkyl; Or, R 1 and R 2 Together with the carbon atom to which it is attached, it forms C 3-6 Cycloalkyl; W is selected from C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 Cycloalkyl, wherein the C 1-6 Alkylene and C 1-6 Alkylene-C 3-6 The cycloalkyl groups are each independently optionally substituted with one or more substituents selected from halogen, hydroxy, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; L 2 Selected from -NR 4 (CH2CH2O)p 1 CH2CH2C(O)-、-NR 4 (CH2CH2O)p 1 CH2C(O)-、-S(CH2)p 1 C(O)- and chemical bonds, where p 1 is an integer from 1 to 20; L 3 A peptide residue consisting of 2 to 7 amino acid residues, wherein the amino acid residues are selected from the group consisting of phenylalanine, alanine, glycine, valine, lysine, citrulline, serine, glutamic acid and aspartic acid, and are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, cyano, amino, alkyl, chloroalkyl, deuterated alkyl, alkoxy and cycloalkyl; R 4 and R 5 is selected from the group consisting of a hydrogen atom, an alkyl group, a haloalkyl group, a deuterated alkyl group, and a hydroxyalkyl group; R 6 and R 7 are the same or different and are each independently selected from a hydrogen atom, a halogen, an alkyl group, a halogenated alkyl group, a deuterated alkyl group and a hydroxyalkyl group.
13. The antibody-drug conjugate or a pharmaceutically acceptable salt thereof represented by the general formula (Pc-LYD) according to any one of claims 10 to 12, which is an antibody-drug conjugate or a pharmaceutically acceptable salt thereof represented by the general formula (Pc-9-A): in: n is 1 to 8; Pc is the anti-TF antibody according to any one of claims 1 to 6.
14. A method for preparing a compound of the general formula (Pc-L a -YD) or a pharmaceutically acceptable salt thereof, comprising the following steps: After Pc reduction, it is combined with the general formula (L a -YD) to produce the compound represented by the general formula (Pc-L a -YD) an antibody-drug conjugate or a pharmaceutically acceptable salt thereof; in: Pc is an anti-TF antibody according to any one of claims 1 to 6; W.L. 2 , L 3 , R 1 , R 2 , R 5 ~R 7 , m and n are as defined in claim 12.
15. A pharmaceutical composition comprising the anti-TF antibody according to any one of claims 1 to 6, or the nucleic acid molecule according to claim 7, or the antibody-drug conjugate according to any one of claims 10 to 13, or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable excipients, diluents or carriers.
16. Use of the anti-TF antibody according to any one of claims 1 to 6, or the nucleic acid molecule according to claim 7, or the antibody-drug conjugate or a pharmaceutically acceptable salt thereof according to any one of claims 10 to 13, or the pharmaceutical composition according to claim 15 in the preparation of a medicament for treating a tumor or cancer; Preferably, the tumor or cancer is selected from breast cancer, pancreatic cancer, lung cancer, esophageal cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, bladder cancer, fallopian tube cancer, peritoneal cancer, colorectal cancer, head and neck cancer and squamous cell carcinoma.
